PRECISION: Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen
Study Details
Study Description
Brief Summary
To answer the question of overall benefit: risk of celecoxib when compared to two most commonly prescribe traditional (non-selective) nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of arthritis pain. For this purpose, patients with osteoarthritis or rheumatoid arthritis with or at risk of developing cardiovascular disease will be recruited. The cardiovascular, gastrointestinal and renal safety and symptomatic benefit in each treatment group will be assessed accordingly.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 4 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: celecoxib subject receives celecoxib and dummy (placebo) ibuprofen and naproxen |
Drug: celecoxib
100 to 200 mg twice daily, taken by mouth
|
Active Comparator: ibuprofen subject receives ibuprofen and dummy (placebo) celecoxib and naproxen |
Drug: Ibuprofen
ibuprofen 600 mg to 800 mg three times daily, taken by mouth
|
Active Comparator: naproxen subject receives naproxen and dummy (placebo) celecoxib and ibuprofen |
Drug: Naproxen
naproxen 375mg to 500 mg twice daily, taken by mouth
|
Outcome Measures
Primary Outcome Measures
- The First Occurrence of Antiplatelet Trialists Collaboration (APTC) Composite Endpoint, Confirmed by the Clinical Events Committee (CEC). [Intent to Treat (ITT) Population - 30 months; Modified ITT (MITT) Population - 42 months]
APTC events are defined as a composite of any of the following events: Death due to CV causes (including cardiac, cerebrovascular, venous thromboembolic, haemorrhagic, other vascular, or unknown cause); Non-fatal MI; Non-fatal stroke (including intracranial hemorrhages, stroke of ischemic or unknown etiology).
Secondary Outcome Measures
- The First Occurrence of a Major Adverse Cardiovascular Events (MACE) [ITT Population - 30 months; MITT Population - 42 months]
MACE defined as the composite of CV death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA
- The First Occurrence of Clinically Significant Gastrointestinal Events (CSGIE) [ITT Population - 30 months; MITT Population - 42 months]
CSGIE include: Gastroduodenal (GD) hemorrhage, Gastric outlet obstruction, Gastroduodenal, small bowel or large bowel perforation, Large bowel hemorrhage, Small bowel hemorrhage, Acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage, Symptomatic gastric or duodenal ulcer
- Change From Baseline in Patient's Assessment of Arthritis Pain (VAS) [ITT and MITT Population - Baseline to 42 months]
VAS question "How much pain do you have" was graded on a scale from 0 to 100 with 0 indicating "No pain" and 100 indicating "Worst possible pain".
Eligibility Criteria
Criteria
Inclusion Criteria:
- Subjects with osteoarthritis or rheumatoid Arthritis with or at risk of developing cardiovascular disease and who require and eligible for chronic, daily therapy with an NSAID to control arthritis sign and symptoms.
Exclusion Criteria:
-
Subjects have had a recent cardiovascular event, unstable cardiovascular conditions, or any major surgery (cardiac or non-cardiac) within 3 months prior to randomization;
-
Subjects with medical or laboratory abnormality that would make the subject inappropriate for entry into this trial
-
Subjects require treatment with aspirin > 325 mg /day
-
Subjects with known hypersensitivity to celecoxib, ibuprofen, naproxen, aspirin or esomeprazole, etc.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Carol M. Johnson MD, LLC | Alabaster | Alabama | United States | 35007 |
2 | Orthopaedics West | Bessemer | Alabama | United States | 35022 |
3 | Central Alabama Research | Birmingham | Alabama | United States | 35209 |
4 | Simon Williamson Clinic/Clinical Research Advantage, Inc. | Birmingham | Alabama | United States | 35211 |
5 | Achieve Clinical Research, LLC | Birmingham | Alabama | United States | 35216 |
6 | Alabama Clinical Therapeutics, LLC | Birmingham | Alabama | United States | 35235 |
7 | Cahaba Research Inc. | Birmingham | Alabama | United States | 35242 |
8 | Winston Technology Inc. | Haleyville | Alabama | United States | 35565 |
9 | Clinical Research Consultants, Inc | Hoover | Alabama | United States | 35216 |
10 | Medical Affiliated Research Center, Incorporated | Huntsville | Alabama | United States | 35801 |
11 | Rheumatology Associates of North Alabama, PC | Huntsville | Alabama | United States | 35801 |
12 | Montgomery Rheumatology Associates | Montgomery | Alabama | United States | 36111 |
13 | James P. Beretta, PC | Pelham | Alabama | United States | 35124 |
14 | Alabama Clinical Research Associates | Pell City | Alabama | United States | 35128 |
15 | Pell City Internal and Family Medicine | Pell City | Alabama | United States | 35215 |
16 | Scottsboro Quick Care Clinic | Scottsboro | Alabama | United States | 35768 |
17 | Clinic for Rheumatic Diseases | Tuscaloosa | Alabama | United States | 35406 |
18 | Terence T. Hart , MD | Tuscumbia | Alabama | United States | 35674 |
19 | Clinical Research Advantage Inc./ Warner Family Practice, PC | Chandler | Arizona | United States | 85224 |
20 | ArthroCare, Arthritis Care & Research P.C. | Gilbert | Arizona | United States | 85234 |
21 | Clinical Research Advantage Inc., /Thunderbird Internal Medicine | Glendale | Arizona | United States | 85306-4652 |
22 | Arizona Center for Clinical Research | Glendale | Arizona | United States | 85306 |
23 | Clinical Research Advantage, Inc./ Lenzmeier Family Medicine | Glendale | Arizona | United States | 85308 |
24 | Clinical Research Advantage, Inc./Central Arizona Medical Associates, PC | Mesa | Arizona | United States | 85206 |
25 | Novara Clinical Research | Mesa | Arizona | United States | 85206 |
26 | Clinical Research Advantage, Inc. | Mesa | Arizona | United States | 85213 |
27 | Sun Valley Arthritis Center, Limited | Peoria | Arizona | United States | 85381 |
28 | Lovelace Scientific Resources, Inc. | Phoenix | Arizona | United States | 85016 |
29 | Clinical Research Advantage, Inc./ Family Practice Specialists, LTD | Phoenix | Arizona | United States | 85018 |
30 | NPHC Research | Phoenix | Arizona | United States | 85020 |
31 | Phoenix Clinical | Phoenix | Arizona | United States | 85021 |
32 | Arizona Research Center, Inc. | Phoenix | Arizona | United States | 85023 |
33 | Precision Trials AZ. LLC; AZ | Phoenix | Arizona | United States | 85032 |
34 | 43rd Medical Associates, P.C. | Phoenix | Arizona | United States | 85051 |
35 | Southwest Health Ltd. | Scottsdale | Arizona | United States | 85254 |
36 | Advanced Arthritis Care and Research | Scottsdale | Arizona | United States | 85258 |
37 | Arizona Pain Specialist, PLLC | Scottsdale | Arizona | United States | 85258 |
38 | Sonora Quest Laboratories | Scottsdale | Arizona | United States | 85258 |
39 | Cochise Clinical Research | Sierra Vista | Arizona | United States | 85635 |
40 | Clinical Research Advantage, Inc./Skyline Medical Center PC | Tempe | Arizona | United States | 85282 |
41 | Clinical Research Advantage, Inc./Urban Family Practice Associates, PC | Tempe | Arizona | United States | 85282 |
42 | Clinical Research Advantage, Inc./Warner Family Practice, PC | Tempe | Arizona | United States | 85282 |
43 | Clinical Research Advantage, Inc/Manning Family Care | Tempe | Arizona | United States | 85282 |
44 | Clinical Research Advantage, Incl Colorado Springs Health Partners, East | Tempe | Arizona | United States | 85282 |
45 | Family Medicine Associates/Clinical Research Advantage | Tempe | Arizona | United States | 85282 |
46 | Clinical Research Advantage, Inc./Fiel Family and Sports Medicine, PC | Tempe | Arizona | United States | 85283 |
47 | ARA-Arizona Research Associates | Tucson | Arizona | United States | 85712 |
48 | Canyon Clinical Research LLC | Tucson | Arizona | United States | 85712 |
49 | Tucson Clinical Researh | Tucson | Arizona | United States | 85712 |
50 | ACRC/Arizona Clinical Research Center, Incorporated | Tucson | Arizona | United States | 85715 |
51 | Clinical Research Advantage, Inc./ Orange Grove Family Practice | Tucson | Arizona | United States | 85741 |
52 | Genova Clinical Research | Tucson | Arizona | United States | 85741 |
53 | Eclipse Clinical Research | Tucson | Arizona | United States | 85745 |
54 | Fayetteville Diagnostic Clinic Limited | Fayetteville | Arkansas | United States | 72703 |
55 | Hearne Family Practice Clinic | Little Rock | Arkansas | United States | 72205 |
56 | Larry S. Watkins, M.D. | Little Rock | Arkansas | United States | 72205 |
57 | Lynn Institute of the Ozarks | Little Rock | Arkansas | United States | 72205 |
58 | Rx Medical Research of AR | Little Rock | Arkansas | United States | 72205 |
59 | Anaheim Family Medical Center | Anaheim | California | United States | 92804 |
60 | Advanced Research Center | Anaheim | California | United States | 92805 |
61 | Advanced Arthritis & Rheumatology Center | Artesia | California | United States | 90701 |
62 | Bina Akamdar MD | Azusa | California | United States | 91702 |
63 | Rx for Life, Inc | Bell | California | United States | 90201 |
64 | Clinical Research Advantage Inc., /Cassidy Medical Group-Carlsbad | Carlsbad | California | United States | 92008 |
65 | Capitol Interventional Cardiology | Carmichael | California | United States | 95608 |
66 | Northern California Research | Carmichael | California | United States | 95608 |
67 | CORE Orthopaedic Medical Center | Encinitas | California | United States | 92024 |
68 | Arthritis Medical Clinic of North County, Inc. | Escondido | California | United States | 92025 |
69 | Med Investigations, Inc. | Fair Oaks | California | United States | 95628 |
70 | Valley Research | Fresno | California | United States | 93720 |
71 | Creekside Clinical Research | Greenbrae | California | United States | 94904 |
72 | C. V. Mehta, MD Medical Corporation | Hemet | California | United States | 92543 |
73 | Talbert Medical Group | Huntington Beach | California | United States | 92646 |
74 | Alia Clinical Research, Inc | Huntington Park | California | United States | 90255 |
75 | Time Clinical Research Inc. | Huntington Park | California | United States | 90255 |
76 | Lindora Research Center | Irvine | California | United States | 92604 |
77 | Office of Dr. Robert L. Freed, MD | Irvine | California | United States | 92618 |
78 | Office of Dr. Alan Schenk | Laguna Hills | California | United States | 92653 |
79 | Prime Care Clinical Research | Laguna Hills | California | United States | 92653 |
80 | Jeremy Anuntiyo | Lakewood | California | United States | 90712 |
81 | Premiere Clinical Research, LLC | Lakewood | California | United States | 90712 |
82 | Stuart J. Finkelstein | Lakewood | California | United States | 90712 |
83 | Clinical Trials Research | Lincoln | California | United States | 95648 |
84 | VA Loma Linda Healthcare System | Loma Linda | California | United States | 92357 |
85 | Narbonne Multi-Specialty Medical Group Inc. | Lomita | California | United States | 90717 |
86 | Office of Dr. Arvind J. Mehta | Long Beach | California | United States | 90806 |
87 | Pacific Internal Medicine Group, Inc | Long Beach | California | United States | 90806 |
88 | Long Beach Center for Clinical Research | Long Beach | California | United States | 90807-0000 |
89 | National Institute of Clinical Research | Long Beach | California | United States | 90807 |
90 | Alliance Research, LLC | Long Beach | California | United States | 90813 |
91 | Valerius Medical Group and Research Center | Los Alamitos | California | United States | 90720 |
92 | IMD Medical Group | Los Angeles | California | United States | 90029 |
93 | Pacific Arthritis Care Center | Los Angeles | California | United States | 90045 |
94 | Wagdy W. Kades, MD, Inc. | Los Angeles | California | United States | 90057 |
95 | Samaritan Center for Medical Research Medical Group | Los Gatos | California | United States | 95032 |
96 | Office of Lewis Gamarra, MD M.P.H. | Los Osos | California | United States | 93402 |
97 | Adegbenga A. Adetola, M.D. | Lynwood | California | United States | 90262 |
98 | Facey Medical Group | Mission Hills | California | United States | 91345 |
99 | Providence Clinical Research | North Hollywood | California | United States | 91606 |
100 | Desert Medical Group | Palm Springs | California | United States | 92262 |
101 | The Office of Dr. Marcos Yang | Palos Verdes Estates | California | United States | 90274 |
102 | Bayview Research Group, LLC | Paramount | California | United States | 90723 |
103 | Sierra Rheumatology | Roseville | California | United States | 95661 |
104 | Center for Clinical Trials of Sacramento, Inc. | Sacramento | California | United States | 95823 |
105 | Sacramento Heart and Vascular Research Center | Sacramento | California | United States | 95825 |
106 | California Research Foundation | San Diego | California | United States | 92103-6204 |
107 | San Diego Arthritis Medical Clinic | San Diego | California | United States | 92108 |
108 | Wetlin Research Associates, Inc | San Diego | California | United States | 92120 |
109 | Medical Associates Research Group | San Diego | California | United States | 92123 |
110 | San Jose Valley Research, Inc. | San Jose | California | United States | 95116 |
111 | Comprehensive Adult Risk Evaluation | San Leandro | California | United States | 94578 |
112 | East Bay Rheumatology Medical Group Inc | San Leandro | California | United States | 94578 |
113 | Central Coast Pathology Consultants | San Luis Obispo | California | United States | 93401 |
114 | Coastal Medical Research Group, Inc. | San Luis Obispo | California | United States | 93405 |
115 | Family Medical Center | San Luis Obispo | California | United States | 93405 |
116 | Office of Ajay G. Meka, MD | Santa Ana | California | United States | 92704 |
117 | Pacific Arthritis Center Medical Group | Santa Maria | California | United States | 93454 |
118 | Orrin M. Troum & Medical Associates | Santa Monica | California | United States | 90404 |
119 | Northern California Medical Associates | Santa Rosa | California | United States | 95403 |
120 | Robert Simon, MD | Sherman Oaks | California | United States | 91423 |
121 | St. Joseph Medical Associates | Stockton | California | United States | 95204 |
122 | Westlake Medical Research | Thousand Oaks | California | United States | 91360 |
123 | Paradigm Clinical Research Institute, Inc. | Torrance | California | United States | 90503 |
124 | Orange County Research Center | Tustin | California | United States | 92780 |
125 | Inland Rheumatology and Osteoporosis Medical Group | Upland | California | United States | 91786 |
126 | Inland Rheumatology Clinical Trials, Inc. | Upland | California | United States | 91786 |
127 | Bayview Research Group | Valley Village | California | United States | 91607 |
128 | Medvin Clinical Research | Van Nuys | California | United States | 91405 |
129 | Center for Clinical Trials of San Gabriel | West Covina | California | United States | 91790 |
130 | Agilence Arthritis and Osteoporosis Medical Center, Inc. | Whittier | California | United States | 90606 |
131 | Avalon Family Medical Group | Wilmington | California | United States | 90744 |
132 | Darrell E. Gorman, MD | Arvada | Colorado | United States | 80005 |
133 | Aurora Denver Cardiology Associates | Aurora | Colorado | United States | 80012 |
134 | Azmi Emil Farag, MD | Colorado Springs | Colorado | United States | 80918 |
135 | Lynn Institute of the Rockies | Colorado Springs | Colorado | United States | 80920 |
136 | Colorado Springs Health Partners- East/Clinical Research Advantage | Colorado Springs | Colorado | United States | 80922 |
137 | Mountain View Clinical Research, Inc. | Denver | Colorado | United States | 80209 |
138 | Saint Luke's Medical Clinic | Fort Collins | Colorado | United States | 80525 |
139 | New West Physicians | Golden | Colorado | United States | 80401 |
140 | Ranch View Family Medicine | Highlands Ranch | Colorado | United States | 80130 |
141 | Colorado Center for Bone Research PC | Lakewood | Colorado | United States | 80227 |
142 | South Denver Cardiology Associates, PC | Littleton | Colorado | United States | 80120 |
143 | Lynn Institute of Pueblo | Pueblo | Colorado | United States | 81008 |
144 | Connecticut Clinical Research, LLC | Bridgeport | Connecticut | United States | 06606 |
145 | Connecticut Gastroenterology Institute | Bristol | Connecticut | United States | 06010 |
146 | Arthritis and Osteoporosis Center, PC | Hamden | Connecticut | United States | 06518 |
147 | Robert Lang, MD, P.C. | Hamden | Connecticut | United States | 06518 |
148 | Coastal Connecticut Research, LLC | New London | Connecticut | United States | 06320 |
149 | Office of Edward J. McDermott, Jr., MD | New London | Connecticut | United States | 06320 |
150 | Orthopaedics Foundation for Active Lifestyles | Stamford | Connecticut | United States | 06905 |
151 | Stamford Therapeutics Consortium | Stamford | Connecticut | United States | 06905 |
152 | New England Research Associates, LLC | Trumbull | Connecticut | United States | 06611 |
153 | Arthritis Center of Connecticut | Waterbury | Connecticut | United States | 06708 |
154 | Rheumatology Consultants of Delaware | Lewes | Delaware | United States | 19958 |
155 | Office of Cynthia Morgan, MD | Washington | District of Columbia | United States | 20003 |
156 | The Center for Rheumatology and Bone Research | Washington | District of Columbia | United States | 20006 |
157 | Medical Specialist of the Palm Beaches | Atlantis | Florida | United States | 33462 |
158 | South Florida Medical Research | Aventura | Florida | United States | 33180 |
159 | RASF - Clinical Research Center | Boca Raton | Florida | United States | 33486 |
160 | Orthopedic Research Institute | Boynton Beach | Florida | United States | 33472 |
161 | Clinical Research of Brandon, LLC | Brandon | Florida | United States | 33511 |
162 | Family Healthcare of Chipley | Chipley | Florida | United States | 32428 |
163 | Health First Clinical Research Group, Inc. | Chipley | Florida | United States | 32428 |
164 | Southern Family Healthcare and Health First Research Group Inc. | Chipley | Florida | United States | 32428 |
165 | Florida Research & Testing, LLC | Clearwater | Florida | United States | 33755 |
166 | Alba Clinical Research | Clearwater | Florida | United States | 33756 |
167 | Appletree Medical | Clearwater | Florida | United States | 33756 |
168 | Innovative Research of West Florida, Inc. | Clearwater | Florida | United States | 33756 |
169 | Clinical Research of West Florida | Clearwater | Florida | United States | 33765 |
170 | Rameshwar N. Mathur, MD, PA | Cocoa | Florida | United States | 32927 |
171 | Nature Coast Clinical Research, LLC | Crystal River | Florida | United States | 34429 |
172 | Atlantic Institute of Clinical Research | Daytona Beach | Florida | United States | 32114 |
173 | International Medical Research | Daytona Beach | Florida | United States | 32117 |
174 | Omega Research Consultants, LLC | DeBary | Florida | United States | 32713 |
175 | Physicians Research Alliance, LLC | DeBary | Florida | United States | 32713 |
176 | Deerfield Beach Cardiology Associates | Deerfield Beach | Florida | United States | 33442 |
177 | Doctors Medical Center of Walton County | DeFuniak Springs | Florida | United States | 32435 |
178 | Avail Clinical Research, LLC | DeLand | Florida | United States | 32720 |
179 | Florida Research Associates, LLC/Florida Orthopaedic Associates, P.A. | DeLand | Florida | United States | 32720 |
180 | Cohen Medical Associates, PA | Delray Beach | Florida | United States | 33446 |
181 | Clark Family Medicine & Emerald Coast Research Group | Destin | Florida | United States | 32540 |
182 | SJS Clinical Research, Inc | Destin | Florida | United States | 32541 |
183 | Robert W. Levin MD | Dunedin | Florida | United States | 34698 |
184 | Riverside Clinical Research | Edgewater | Florida | United States | 32132 |
185 | Fleming Island Center for Clinical Research | Fleming Island | Florida | United States | 32003 |
186 | Invesclinic | Fort Lauderdale | Florida | United States | 33308 |
187 | M&O Clinical Research, LLC | Fort Lauderdale | Florida | United States | 33316 |
188 | Maxine Hamilton, MD PA | Fort Lauderdale | Florida | United States | 33316 |
189 | Holy Cross Medical Group Northridge Internal Medicine | Fort Lauderdale | Florida | United States | 33334 |
190 | Clinical Physiology Associates | Fort Myers | Florida | United States | 33912 |
191 | Emerald Coast Mood & Memory | Fort Walton Beach | Florida | United States | 32547 |
192 | White-Wilson Medical Center, PA | Fort Walton Beach | Florida | United States | 32547 |
193 | Cardiology West | Gainesville | Florida | United States | 32605 |
194 | Florida Research Network, LLC | Gainesville | Florida | United States | 32605 |
195 | Southeastern Integrated Medical, PL | Gainesville | Florida | United States | 32607 |
196 | Shands at the University of Florida | Gainesville | Florida | United States | 32610 |
197 | University of Florida | Gainesville | Florida | United States | 32610 |
198 | Genetic Medical Research Corporation | Hialeah | Florida | United States | 33010 |
199 | Direct Helpers Medical Center, Inc. | Hialeah | Florida | United States | 33012 |
200 | Indago Research & Health Center, Inc. | Hialeah | Florida | United States | 33012 |
201 | Reliable Clinical Research, LLC | Hialeah | Florida | United States | 33012 |
202 | Orthopaedic Associates of South Broward, P.A. | Hollywood | Florida | United States | 33021 |
203 | Advanced Research Institute of Miami | Homestead | Florida | United States | 33030 |
204 | Pasco Cardiology Center | Hudson | Florida | United States | 34667 |
205 | Nature Coast Clinical Research | Inverness | Florida | United States | 34452 |
206 | Westside Center for Clinical Research | Jacksonville | Florida | United States | 32205 |
207 | East Coast Institute for Research, LLC | Jacksonville | Florida | United States | 32216 |
208 | Jacksonville Center for Clincal Research | Jacksonville | Florida | United States | 32216 |
209 | St. Vincent's Cardiology | Jacksonville | Florida | United States | 32216 |
210 | Dr. Ricardo A. Bedoya, M.D. | Jupiter | Florida | United States | 33458 |
211 | Drug Study Institute | Jupiter | Florida | United States | 33458 |
212 | Christopher Chappel | Kissimmee | Florida | United States | 34744 |
213 | Florida Arthritis Center, LLC | Lake Mary | Florida | United States | 32746 |
214 | Pedro Ylisastigui, MD | Lehigh Acres | Florida | United States | 33936 |
215 | Adult Medicine Specialists | Longwood | Florida | United States | 32779 |
216 | Genesis Research International | Longwood | Florida | United States | 32779 |
217 | Doctors Inn | Madeira Beach | Florida | United States | 33708 |
218 | Everest Medical Care and Palm Court Research Group | Marianna | Florida | United States | 32446 |
219 | Panhandle Family Care Associates & Emerald Coast Research Group | Marianna | Florida | United States | 32446 |
220 | The Doctor's Office | Marianna | Florida | United States | 32446 |
221 | Health First Medical Group | Melbourne | Florida | United States | 32901 |
222 | Holmes Regional Medical Center | Melbourne | Florida | United States | 32901 |
223 | Pharmaceutical Research Associates | Merritt Island | Florida | United States | 32953 |
224 | Orthopaedic Specialist of Miami Beach | Miami Beach | Florida | United States | 33181 |
225 | AMPM Research Clinic | Miami Gardens | Florida | United States | 33169 |
226 | Crystal Biomedical Research, LLC | Miami Lakes | Florida | United States | 33014 |
227 | Pembroke Clinical Trials | Miami Lakes | Florida | United States | 33014 |
228 | Homestead Associates in Research, Inc | Miami | Florida | United States | 33032 |
229 | Pharmax Research Clinic | Miami | Florida | United States | 33126 |
230 | Life Spring Research Foundation | Miami | Florida | United States | 33134 |
231 | Miami International Cardiology Consultants | Miami | Florida | United States | 33137 |
232 | Florida Medical Center & Research, Inc. | Miami | Florida | United States | 33142 |
233 | The Center for Arthritis and Rheumatic Diseases | Miami | Florida | United States | 33143 |
234 | Well Pharma Medical Research Corporation | Miami | Florida | United States | 33143 |
235 | DC Health Clinical Trials | Miami | Florida | United States | 33144 |
236 | School of Clinical Research USA, LLC | Miami | Florida | United States | 33144 |
237 | Advance Medical Research Services, Corp | Miami | Florida | United States | 33165 |
238 | Future Care Solution, LLC | Miami | Florida | United States | 33165 |
239 | New Horizon Research Center | Miami | Florida | United States | 33175 |
240 | Miami Cardiology Group | Miami | Florida | United States | 33176 |
241 | M & M Medical Center | Miami | Florida | United States | 33185 |
242 | Office of Dr. Juvenal E. Martinez, MD, PA | Miami | Florida | United States | 33186 |
243 | Anchor Research Center | Naples | Florida | United States | 34102 |
244 | Jeffrey Alper M.D. Research | Naples | Florida | United States | 34102 |
245 | Anchor Health Centers | Naples | Florida | United States | 34108 |
246 | Medical Surgical Specialists, Physicians Regional Medical Center | Naples | Florida | United States | 34119 |
247 | Suncoast Clinical Research, Inc. | New Port Richey | Florida | United States | 34652 |
248 | Magnolia Research Group, Inc. | Ocala | Florida | United States | 34471-5117 |
249 | Ocala Rheumatology Research Center | Ocala | Florida | United States | 34474 |
250 | Paddock Park Clinical Research | Ocala | Florida | United States | 34474 |
251 | Southeastern Rehabilitation Medicine | Ocala | Florida | United States | 34474 |
252 | Tequesta Research Group | Ocala | Florida | United States | 34474 |
253 | CEC Research, INC. | Ocoee | Florida | United States | 34761 |
254 | Florida Heart Group, PA | Orlando | Florida | United States | 32803-1849 |
255 | Florida Hospital | Orlando | Florida | United States | 32803 |
256 | Compass Research, LLC | Orlando | Florida | United States | 32806 |
257 | DCT FMC, LLC dba Discovery Clinical Trials | Orlando | Florida | United States | 32806 |
258 | DCT-FMC, LLC dba Discovery Clinical Trials | Orlando | Florida | United States | 32806 |
259 | Arthur L. Hall MD PA | Orlando | Florida | United States | 32814 |
260 | Block and Nation, PA | Oviedo | Florida | United States | 32765 |
261 | Arthritis Research of Florida, Inc. | Palm Harbor | Florida | United States | 34684 |
262 | Florida Med Center of Countryside | Palm Harbor | Florida | United States | 34684 |
263 | Rene CaSanova Medical Office Inc | Pembroke Pines | Florida | United States | 33024 |
264 | Boulevard Professional Centre | Pembroke Pines | Florida | United States | 33026 |
265 | Research Physician Network Alliance | Pembroke Pines | Florida | United States | 33026 |
266 | South Broward Research LLC | Pembroke Pines | Florida | United States | 33027 |
267 | South Florida Research Solutions, LLC | Pembroke Pines | Florida | United States | 33029 |
268 | DMI Research, Inc. | Pinellas Park | Florida | United States | 33782 |
269 | Sunbelt Research, LLC | Plantation | Florida | United States | 33322 |
270 | Boca Raton Clinical Research | Plantation | Florida | United States | 33323 |
271 | St. Johns Center for Clinical Research | Ponte Vedra | Florida | United States | 32081 |
272 | Accord Clinical Research, LLC | Port Orange | Florida | United States | 32129 |
273 | Administrative Address: Florida Arthritis & Osteoporosis Center | Port Richey | Florida | United States | 34668 |
274 | Heart & Vascular Center Research | Sarasota | Florida | United States | 34239 |
275 | Edgar R. Blecker, MD | Sebastian | Florida | United States | 32958 |
276 | Phoenix Clinical Research, LLC. | Tamarac | Florida | United States | 33321 |
277 | Clinical Research of West Florida | Tampa | Florida | United States | 33603 |
278 | Soutwest Florida Clinical Research Center | Tampa | Florida | United States | 33609-3018 |
279 | Clinyx/Floria Cardiovascular | Tampa | Florida | United States | 33609 |
280 | Stedman Clinical Trials, LLC | Tampa | Florida | United States | 33613 |
281 | West Wind'r Research | Tampa | Florida | United States | 33613 |
282 | Health Point Medical Group, Inc | Tampa | Florida | United States | 33614 |
283 | Causeway Medical Clinic | Tampa | Florida | United States | 33619-6364 |
284 | Office of Alastair C. Kennedy, MD | Vero Beach | Florida | United States | 32960 |
285 | Metabolic Research Institute, Incorporated | West Palm Beach | Florida | United States | 33401 |
286 | Palm Beach Research Center | West Palm Beach | Florida | United States | 33409 |
287 | Central Florida Primary Care | Winter Park | Florida | United States | 32792 |
288 | Florida Medical Clinic, PA | Zephyrhills | Florida | United States | 33542 |
289 | The Kaufmann Clinic | Atlanta | Georgia | United States | 30308 |
290 | Piedmont Heart Institute | Atlanta | Georgia | United States | 30309 |
291 | Arthritis and Rheumatology of Georgia | Atlanta | Georgia | United States | 30342 |
292 | Atlanta Center for Clinical Research, Corp. | Atlanta | Georgia | United States | 30342 |
293 | Atlanta Vascular Research Foundation | Atlanta | Georgia | United States | 30342 |
294 | Executive Health and Research Associates | Atlanta | Georgia | United States | 30342 |
295 | Southern Clinical Research and Management, Inc. (SCRAM) | Augusta | Georgia | United States | 30904 |
296 | Masters of Clinical Research, Inc. | Augusta | Georgia | United States | 30909 |
297 | Amelia Medical Plaza | Bainbridge | Georgia | United States | 39819 |
298 | Bainbridge Medical Associates | Bainbridge | Georgia | United States | 39819 |
299 | Abdul Bari MD Inc | Cairo | Georgia | United States | 39828 |
300 | Southern Clinical Research Management and Consulting | Cairo | Georgia | United States | 39828 |
301 | North Georgia Rheumatology Group, PC | Duluth | Georgia | United States | 30096 |
302 | United Osteoporosis Centers | Gainesville | Georgia | United States | 30501 |
303 | North Georgia Rheumatology Group, PC | Lawrenceville | Georgia | United States | 30046 |
304 | GCH Research Dr. G Craig Heigerick DO | Lilburn | Georgia | United States | 30047 |
305 | Mercer University Mercer Medicine | Macon | Georgia | United States | 31201 |
306 | Drug Studies America | Marietta | Georgia | United States | 30060 |
307 | Drug Studies America | Marietta | Georgia | United States | 30066 |
308 | Clinical Research Advantage, Inc./Urban Family Practice Associates, PC | Marietta | Georgia | United States | 30067 |
309 | In-Quest Medical Research, LLC | Norcross | Georgia | United States | 30071 |
310 | Harbin Clinic | Rome | Georgia | United States | 30165-1698 |
311 | Atlanta Center for Clinical Research | Roswell | Georgia | United States | 30075 |
312 | Herman Clinical Research, LLC | Suwanee | Georgia | United States | 30024 |
313 | Archibold Primary Care | Thomasville | Georgia | United States | 31792 |
314 | Clinical Trial Providers, Inc. | Tucker | Georgia | United States | 30084 |
315 | VSC | Valdosta | Georgia | United States | 31602 |
316 | Kaufmann Clinic, INC | Woodstock | Georgia | United States | 30188 |
317 | North Georgia Clinical Research | Woodstock | Georgia | United States | 30189 |
318 | North Georgia Internal Medicine | Woodstock | Georgia | United States | 30189 |
319 | East-West Medical Research Institute | Honolulu | Hawaii | United States | 96814 |
320 | Orthopedic Health Care Clinic | Boise | Idaho | United States | 83702 |
321 | Sonora Clinical Research, LLC | Boise | Idaho | United States | 83702 |
322 | Eagle's View Family Medicine | Boise | Idaho | United States | 83713-0997 |
323 | Coeur D'Alene Arthritis Clinic | Coeur d'Alene | Idaho | United States | 83814 |
324 | CTL Research | Eagle | Idaho | United States | 83616 |
325 | Women's Healthcare Associates P.A. dba Rosemark WomenCare Specialists | Idaho Falls | Idaho | United States | 83404 |
326 | Idaho Arthritis and Osteoporosis Center | Meridian | Idaho | United States | 83642-6356 |
327 | Advanced Clinical Research | Meridian | Idaho | United States | 83642 |
328 | AMR Sakeena Research | Aurora | Illinois | United States | 60506 |
329 | Arthur I Davida, MD PC | Bloomingdale | Illinois | United States | 60108 |
330 | Cardiac Wellness Consultants | Chicago | Illinois | United States | 60611 |
331 | Chicago Peripheral Nerve Center | Chicago | Illinois | United States | 60611 |
332 | ICCT Research International Incorporated | Chicago | Illinois | United States | 60611 |
333 | Claude Mandel Medical Center | Chicago | Illinois | United States | 60617 |
334 | Windy City Orthopedics and Sports Medicine | Evanston | Illinois | United States | 60202 |
335 | South Suburban Health Professional Group | Hazel Crest | Illinois | United States | 60429 |
336 | Prairie Rheumatology Associates, SC | Joliet | Illinois | United States | 60435 |
337 | Lake Zurich Family Treatment Center | Lake Zurich | Illinois | United States | 60047 |
338 | Southern Illiniois Clinical Research Centre | O'Fallon | Illinois | United States | 62269 |
339 | Speciality phhysicians of Illinois, LLC | Olympia Fields | Illinois | United States | 60461 |
340 | Redhead Research Inc., DBA Research Associates of Central Illinois | Peoria | Illinois | United States | 61614 |
341 | Trinity Medical Center | Rock Island | Illinois | United States | 61201 |
342 | Rockford Health Physicians | Rockford | Illinois | United States | 61103 |
343 | Prairie Cardiovascular Consultants | Springfield | Illinois | United States | 62701 |
344 | Prairie Education & Research | Springfield | Illinois | United States | 62701 |
345 | Springfield Clinic | Springfield | Illinois | United States | 62702 |
346 | Springfield Clinic | Springfield | Illinois | United States | 62703 |
347 | Deerbrook Medical Associates | Vernon Hills | Illinois | United States | 60061 |
348 | Community Clinical Research Center | Anderson | Indiana | United States | 46011 |
349 | American Health Network of Indiana, LLC | Avon | Indiana | United States | 46123 |
350 | Robert D. Barnes, MD, LLC | Evansville | Indiana | United States | 47710 |
351 | Clinical Research Advantage, Inc. | Evansville | Indiana | United States | 47714 |
352 | Destiny Clinical Research, LLC | Evansville | Indiana | United States | 47714 |
353 | Clinical Research Advantage/Family Medicine Associates | Evansville | Indiana | United States | 47725 |
354 | American Health Network of Indiana, LLC | Franklin | Indiana | United States | 46131 |
355 | Internal Medicine Center of Northwest Indiana, P.C. | Gary | Indiana | United States | 46409 |
356 | Beacon Medical Group Rheumatology | Granger | Indiana | United States | 46530 |
357 | American Health Network of IN, LLC | Greenfield | Indiana | United States | 46140-2834 |
358 | Diagnostic Rheumatology And Research, PC | Indianapolis | Indiana | United States | 46227 |
359 | Investigators research Group | Indianapolis | Indiana | United States | 46234 |
360 | Dawes Fretzin Clinical Research Group, LLC | Indianapolis | Indiana | United States | 46256 |
361 | Dawes Fretzin Dermatology Group, LLC | Indianapolis | Indiana | United States | 46256 |
362 | Arthritis Associates of Southern Indiana | Jeffersonville | Indiana | United States | 47130 |
363 | Research Institute of Middle America/River Cities Cardiology | Jeffersonville | Indiana | United States | 47130 |
364 | Beacon Medical Group LaPorte | LaPorte | Indiana | United States | 46350 |
365 | Cardiovascular Clinics, PC | Merrillville | Indiana | United States | 46410 |
366 | Community Clinical Research Center | Muncie | Indiana | United States | 47304 |
367 | Medical Specialists Clinical Research Center | Munster | Indiana | United States | 46321 |
368 | Medical Specialists | Munster | Indiana | United States | 46321 |
369 | Arthritis Associates of Southern Indiana | New Albany | Indiana | United States | 47150 |
370 | Buynak Clinical Research | Valparaiso | Indiana | United States | 46383 |
371 | Physician's Clinic of Iowa, PC | Cedar Rapids | Iowa | United States | 52403 |
372 | Ridge Family Practice, PC/Clinical Research Advantage, Inc. | Council Bluffs | Iowa | United States | 51503 |
373 | Midwest Cardiovascular Research Foundation | Davenport | Iowa | United States | 52803 |
374 | Office of Jerrold V Flatt | Des Moines | Iowa | United States | 50316 |
375 | Medical Associates Clinic, PC | Dubuque | Iowa | United States | 52002 |
376 | Family Health Center of Waterloo, PC | Waterloo | Iowa | United States | 50701 |
377 | Northeast IA Medical Education Foundation/Family Practice Center | Waterloo | Iowa | United States | 50702 |
378 | Heartland Research Associates LLC | Arkansas City | Kansas | United States | 67005 |
379 | Community House of Wellness | Kansas City | Kansas | United States | 66104 |
380 | Associates Reseach Inc. | Lansing | Kansas | United States | 66043 |
381 | Radiant Research, Inc. | Overland Park | Kansas | United States | 66210 |
382 | International Clinical Research Institute, Inc | Overland Park | Kansas | United States | 66211 |
383 | Arthritis Specialists of Greater KC | Overland Park | Kansas | United States | 66215 |
384 | Pinnacle Medical Research | Overland Park | Kansas | United States | 66215 |
385 | Quivira Internal Medicine | Overland Park | Kansas | United States | 66215 |
386 | Health Science Research Center | Pratt | Kansas | United States | 67124 |
387 | Heartland Research Associates, LLC | Wichita | Kansas | United States | 67205 |
388 | Via Christi Clinic | Wichita | Kansas | United States | 67208 |
389 | Howard L. Feinberg, D.O. | Ashland | Kentucky | United States | 41101 |
390 | Graves Gilbert Clinic | Bowling Green | Kentucky | United States | 42101-1759 |
391 | Graves Gilbert Clinic | Bowling Green | Kentucky | United States | 42101 |
392 | Internal Medicine Research Association | Campbellsville | Kentucky | United States | 42718 |
393 | Center for Arthritis and Osteoporosis | Elizabethtown | Kentucky | United States | 42701 |
394 | Arthritis Center of Lexington | Lexington | Kentucky | United States | 40504 |
395 | Kentuckiana Center for Better Bone and Joint Health | Louisville | Kentucky | United States | 40202 |
396 | KY Research PLLC. | Louisville | Kentucky | United States | 40202 |
397 | University Medical Associates | Louisville | Kentucky | United States | 40202 |
398 | Louisville Metabolic and Atherosclerosis Research Center | Louisville | Kentucky | United States | 40213 |
399 | Office of Gaurang B. Shah,MD, PSC | Richmond | Kentucky | United States | 40475 |
400 | Richmond Regional Research | Richmond | Kentucky | United States | 40475 |
401 | Chandler Family Practice | Bossier City | Louisiana | United States | 71111 |
402 | McFarland Family Clinic | Shreveport | Louisiana | United States | 71105 |
403 | TFD Research, LLC | Shreveport | Louisiana | United States | 71115 |
404 | Maine Research Associates | Auburn | Maine | United States | 04210 |
405 | Southern Maine Health Care | Biddeford | Maine | United States | 04005 |
406 | Central Maine Heart & Vascular Institute | Lewiston | Maine | United States | 04240 |
407 | Chesapeake CardioVascular Associates | Baltimore | Maryland | United States | 21204 |
408 | Midatlantic Cardiovascular Associates | Baltimore | Maryland | United States | 21204 |
409 | Midatlantic Cardiovascular Associates, PA | Baltimore | Maryland | United States | 21208 |
410 | Health Trends Research, LLC | Baltimore | Maryland | United States | 21209 |
411 | One Heart, LLC | Baltimore | Maryland | United States | 21215 |
412 | Chesapeake CardioVascular Associates | Baltimore | Maryland | United States | 21218 |
413 | Midatlantic Cardiovascular Associates, Pa | Baltimore | Maryland | United States | 21229 |
414 | Saint Agnes HealthCare Incorporated | Baltimore | Maryland | United States | 21229 |
415 | Stephen R Smith, MD FACP | Baltimore | Maryland | United States | 21234-4607 |
416 | MidAtlantic Cardiovascular Associates, PA | Baltimore | Maryland | United States | 21237 |
417 | Peter A. Holt | Baltimore | Maryland | United States | 21239 |
418 | Midatlantic Cardiovascular Associates PA | Bel Air | Maryland | United States | 21014 |
419 | Shah Associates MD, LLC | Charlotte Hall | Maryland | United States | 20622 |
420 | Cardiovascular Specialists, LLC | Columbia | Maryland | United States | 21044-2914 |
421 | Johns Hopkins University | Columbia | Maryland | United States | 21044 |
422 | The Osteoporosis & Clinical Trials Center | Cumberland | Maryland | United States | 21502 |
423 | Arthritis Treatment Center | Frederick | Maryland | United States | 21702 |
424 | The Spine & Joint Center | Greenbelt | Maryland | United States | 20770 |
425 | Klein & Associates, MD, PA | Hagerstown | Maryland | United States | 21740 |
426 | Community Health Research | North East | Maryland | United States | 21901 |
427 | MD Medical Research | Oxon Hill | Maryland | United States | 20745 |
428 | Shah Associates | Prince Frederick | Maryland | United States | 20678 |
429 | Cardiac Associates, Shady Grove Adventist Hospital | Rockville | Maryland | United States | 20850 |
430 | The Center for Rheumatology and Bone Research | Rockville | Maryland | United States | 20850 |
431 | Rockville Internal Medicine Group | Rockville | Maryland | United States | 20854 |
432 | IRC Clinics | Towson | Maryland | United States | 21204 |
433 | Midatlantic Cardiovascular Associates, P.A. | Westminster | Maryland | United States | 21157-6160 |
434 | The Center for Rheumatology and Bone Research | Wheaton | Maryland | United States | 20902 |
435 | Primary Care Cardiology Research | Ayer | Massachusetts | United States | 01432 |
436 | Genesis Clinical Research & Consulting | Fall River | Massachusetts | United States | 02720 |
437 | NECCR Internal Medicine and Cardiology Associates, LLC | Fall River | Massachusetts | United States | 02720 |
438 | Phase III Clinical Research | Fall River | Massachusetts | United States | 02720 |
439 | Pentucket Medical Associates, Incorporated | Haverhill | Massachusetts | United States | 01830 |
440 | Clinical Research Center of Cape Cod, Inc. | Hyannis | Massachusetts | United States | 02601 |
441 | Charles River Medical Associates, Pchi | Natick | Massachusetts | United States | 01760 |
442 | Novex Clinical Research, LLC | New Bedford | Massachusetts | United States | 02740 |
443 | Northampton Internal Medicine Associates, PC | Northampton | Massachusetts | United States | 01062 |
444 | FutureCare Studies | Springfield | Massachusetts | United States | 01105 |
445 | Reliant Medical Group, Inc. | Worcester | Massachusetts | United States | 01605 |
446 | Great Lakes Research Group, Incorporated | Bay City | Michigan | United States | 48706 |
447 | Professional Clinical Research-Benzonia | Benzonia | Michigan | United States | 49616 |
448 | Cadillac Clinical Research | Cadillac | Michigan | United States | 49601 |
449 | Livernois Family Medical Services | Detroit | Michigan | United States | 48221 |
450 | Office of Dr. Susan Courtnage | Eaton Rapids | Michigan | United States | 48827 |
451 | McLaren Regional Medical Center-Research Dept. | Flint | Michigan | United States | 48532 |
452 | Grand Valley Medical Specialist, PLC | Grand Rapids | Michigan | United States | 49506 |
453 | Spectrum Health Medical Group-Rheumatology | Grand Rapids | Michigan | United States | 49506 |
454 | Michigan Medical Cardiovascular PC | Grand Rapids | Michigan | United States | 49546 |
455 | Professional Clinical Research | Interlochen | Michigan | United States | 49643 |
456 | Justus J Fiechtner, MD | Lansing | Michigan | United States | 48910-8595 |
457 | Michigan Cardiovascular Institute | Saginaw | Michigan | United States | 48601 |
458 | Synergy Medical Education Alliance | Saginaw | Michigan | United States | 48602 |
459 | Shores Rheumatology | Saint Clair Shores | Michigan | United States | 48081 |
460 | Oakland Medical Research Center | Troy | Michigan | United States | 48085 |
461 | Troy Internal Medicine Research | Troy | Michigan | United States | 48098 |
462 | St. Luke's Hospital Association of Duluth, DBA St Luke's Rheumatology Assoc. | Duluth | Minnesota | United States | 55805 |
463 | St. Luke's Hospital Association of Duluth, Inc. | Duluth | Minnesota | United States | 55805 |
464 | St. Luke's Hospital Association of Duluth | Duluth | Minnesota | United States | 55805 |
465 | Central Minnesota Heart Center at St. Cloud Hospital | Saint Cloud | Minnesota | United States | 56303-1901 |
466 | St. Paul Heart Clinic | Saint Paul | Minnesota | United States | 55102 |
467 | The Center for Clinical Trials | Biloxi | Mississippi | United States | 39531 |
468 | Planters Clinic | Port Gibson | Mississippi | United States | 39150 |
469 | North Mississippi Medical Clinics, Inc. | Tupelo | Mississippi | United States | 38801 |
470 | Cape Girardeau Physicians Associates | Cape Girardeau | Missouri | United States | 63703 |
471 | Patterson Medical Clinic / d.b.a. Prime Care Research Associates | Florissant | Missouri | United States | 63031 |
472 | Allergy Asthma Immunology Services, LLC | Jefferson City | Missouri | United States | 65101 |
473 | Jefferson City Medical Group | Jefferson City | Missouri | United States | 65109 |
474 | University of Missouri Kansas City School of Medicine | Kansas City | Missouri | United States | 64108-2792 |
475 | Truman Medical Center, Inc. | Kansas City | Missouri | United States | 64108 |
476 | Clinical Research Advantage, Inc./Manning Family Care, LLC | Kansas City | Missouri | United States | 64133 |
477 | St. Louis Center for Clinical Research | Saint Louis | Missouri | United States | 63128 |
478 | Physician Groups, LC, DBA Rheumatology and Internal Medicine Associates | Saint Louis | Missouri | United States | 63131 |
479 | Southampton Healthcare, Inc. | Saint Louis | Missouri | United States | 63139-2909 |
480 | Barbara A. Caciolo, MD | Saint Louis | Missouri | United States | 63139 |
481 | A & A Pain Institute | Saint Louis | Missouri | United States | 63141 |
482 | Sundance Clinical Research, LLC | Saint Louis | Missouri | United States | 63141 |
483 | Mercy Medical Research Institute | Springfield | Missouri | United States | 65807 |
484 | Patients First Health Care, LLC | Washington | Missouri | United States | 63090 |
485 | Glacier View Research Institute, Cardiology | Kalispell | Montana | United States | 59901 |
486 | Alliance Medical Center | Alliance | Nebraska | United States | 69301 |
487 | Cody Medical Associates | Alliance | Nebraska | United States | 69301 |
488 | Bellevue Family Practice/Clinical Research Advantage, Inc. | Bellevue | Nebraska | United States | 68005 |
489 | Clinical Research Advantage, Inc./ Skyline Medical Center, PC | Elkhorn | Nebraska | United States | 68022 |
490 | Clinical Research Advantage, Inc./Prairie Fields Family Medicine, PC | Fremont | Nebraska | United States | 68025 |
491 | Internal Medicine Associates, PC | Grand Island | Nebraska | United States | 68803 |
492 | Physician, Research Collaboration, Southwest Family Health | Lincoln | Nebraska | United States | 68512 |
493 | Lincoln Internal Medicine Associates | Lincoln | Nebraska | United States | 68516 |
494 | Platte River Nephrology | North Platte | Nebraska | United States | 69101 |
495 | Quality Clinical Research LLC | Omaha | Nebraska | United States | 68114 |
496 | Westroads Medical Group | Omaha | Nebraska | United States | 68114 |
497 | Heartland Clinical Research, Inc. | Omaha | Nebraska | United States | 68134 |
498 | Clinical Research Advantage, Inc./Primary Care Physicians, LLP | Omaha | Nebraska | United States | 68144 |
499 | Clinical Research Advantage, Inc. | Henderson | Nevada | United States | 89014 |
500 | Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC | Henderson | Nevada | United States | 89052 |
501 | Sierra Internal Medicine Associates | Incline Village | Nevada | United States | 89451 |
502 | Clinical Research Center of Nevada | Las Vegas | Nevada | United States | 89104 |
503 | Clinical Research Advantage/Peter Philander, MD | Las Vegas | Nevada | United States | 89128 |
504 | Rancho Internal Medicine | Las Vegas | Nevada | United States | 89128 |
505 | Steven D. Folkerth, MD | Las Vegas | Nevada | United States | 89130 |
506 | Ladner Family Practice | Las Vegas | Nevada | United States | 89146 |
507 | VA Southern Nevada Healthcare System | North Las Vegas | Nevada | United States | 89086 |
508 | Arthritis Center of Reno | Reno | Nevada | United States | 89502 |
509 | New Jersey Physicians, LLC | Clifton | New Jersey | United States | 07012 |
510 | Clifton-Wallington Medical Group | Clifton | New Jersey | United States | 07013 |
511 | Anderson and Collins, Clinical Research Inc. | Edison | New Jersey | United States | 08817 |
512 | Drs. Collins and Uthappa | Edison | New Jersey | United States | 08817 |
513 | Central Jersey Health Care | Elizabeth | New Jersey | United States | 07202 |
514 | Andron Medical Associates | Englewood | New Jersey | United States | 07631-2507 |
515 | Advocare Heights Primary Care | Haddon Heights | New Jersey | United States | 08035 |
516 | Hazlet Health Care | Hazlet | New Jersey | United States | 07730 |
517 | Family Care Physicians | Lawrenceville | New Jersey | United States | 08648 |
518 | Penn Cardiac Care at Mercer Bucks | Lawrenceville | New Jersey | United States | 08648 |
519 | Family Medicine of Lindenwold | Lindenwold | New Jersey | United States | 08021 |
520 | Rheumatology and Arthritis Associates PC | Medford | New Jersey | United States | 08055 |
521 | Adult & Pediatric Rheumatology | Midland Park | New Jersey | United States | 07432-1969 |
522 | The Valley Hospital | Ridgewood | New Jersey | United States | 07450 |
523 | Maynard Holgado LLC | Sicklerville | New Jersey | United States | 08081 |
524 | Shore Health Group | Toms River | New Jersey | United States | 08753 |
525 | Hopewell Valley Medical Group, P.A. | Trenton | New Jersey | United States | 08618 |
526 | Arthritis, Rheumatic and Back Disease Associates, PA | Voorhees | New Jersey | United States | 08043 |
527 | Lourdes Medical Associates | Willingboro | New Jersey | United States | 08046 |
528 | Kenneth F. Solinsky, MD | Babylon | New York | United States | 11702-2516 |
529 | LifeLine Research Institute | Brooklyn | New York | United States | 11214 |
530 | Lee Medical Associates | Dunkirk | New York | United States | 14048 |
531 | AMS Research | Elmira | New York | United States | 14905 |
532 | Regional Clinical Research, Inc. | Endwell | New York | United States | 13760 |
533 | Drug Trials America, Inc. | Hartsdale | New York | United States | 10530 |
534 | United Health Service Hospitals, Office of Clinical Trials | Johnson City | New York | United States | 13790 |
535 | IMA Medical Research PC | Kew Gardens | New York | United States | 11415 |
536 | NYU Langone Medical Center, Laura and Issac Perlmutter Cancer Center, Infusion Center | Lake Success | New York | United States | 11042 |
537 | NYU Langone Medical Center, Laura and Issac Perlmutter Cancer Center, Investigational Pharmacy | Lake Success | New York | United States | 11042 |
538 | NYU Langone Rheumatology Associates Long Island | Lake Success | New York | United States | 11042 |
539 | Office of Dr. Allen Chodock | Mamaroneck | New York | United States | 10543 |
540 | Winthrop University Hospital / Clinical Trials Center | Mineola | New York | United States | 11501 |
541 | New York University Pain Management Center | New York | New York | United States | 10016-4974 |
542 | NYU Pain Research | New York | New York | United States | 10016 |
543 | Office of Dr. Richard Stern | New York | New York | United States | 10021 |
544 | DiGiovanna Family Care Center | North Massapequa | New York | United States | 11758 |
545 | Hudson Valley Heart Center | Poughkeepsie | New York | United States | 12601 |
546 | AAIR Research Center | Rochester | New York | United States | 14618 |
547 | Institute for Clinical Studies | Rosedale | New York | United States | 11422 |
548 | Rheumatology Associates of Long Island | Smithtown | New York | United States | 11787-2817 |
549 | Office of Dr. Chadia Morcos | Syosset | New York | United States | 11791 |
550 | Arthritis Health Associates | Syracuse | New York | United States | 13210-1775 |
551 | Crouse Medical Practice, PLLC d/b/a Internist Associates of Central New York | Syracuse | New York | United States | 13210 |
552 | East Meadow Family Practice Associates, PC | Wantagh | New York | United States | 11793 |
553 | Southgate Medical Group | West Seneca | New York | United States | 14224 |
554 | Great Lakes Medical Research | Westfield | New York | United States | 14787 |
555 | Buffalo Cardiology and Pulmonary Associates, PC | Williamsville | New York | United States | 14221 |
556 | Upstate Clinical Research Associates | Williamsville | New York | United States | 14221 |
557 | Asheville Arthritis & Osteoporosis, PA | Asheville | North Carolina | United States | 28803 |
558 | Kernodle Clinic Inc. | Burlington | North Carolina | United States | 27215 |
559 | Calabash Medical Center | Calabash | North Carolina | United States | 28467 |
560 | PMG Research of Raleigh, LLC d/b/a PMG Research of Cary | Cary | North Carolina | United States | 27518 |
561 | Chapel Hill Family Medicine | Chapel Hill | North Carolina | United States | 27514 |
562 | Thurston Arthritis Reaserch Ctr | Chapel Hill | North Carolina | United States | 27599 |
563 | Mid Carolina Cardiology Research | Charlotte | North Carolina | United States | 28204 |
564 | Presbyterian Novant Heart and Wellness | Charlotte | North Carolina | United States | 28204 |
565 | Arthritis and Osteoporosis Consultants of the Carolinas | Charlotte | North Carolina | United States | 28207-1198 |
566 | PMG Research of Charlotte | Charlotte | North Carolina | United States | 28209-3734 |
567 | Barat Research Group, Inc. | Charlotte | North Carolina | United States | 28262 |
568 | Sensenbrenner Primary Care | Charlotte | North Carolina | United States | 28277 |
569 | Duke Health Center at Pickett Road | Durham | North Carolina | United States | 27705 |
570 | Bland Clinic, PA | Greensboro | North Carolina | United States | 27401 |
571 | Medication Management, LLC | Greensboro | North Carolina | United States | 27408 |
572 | Physicians East P. A. | Greenville | North Carolina | United States | 27834 |
573 | Physicians East, PA | Greenville | North Carolina | United States | 27834 |
574 | Clinical Trials of America, Inc. | Hickory | North Carolina | United States | 28601 |
575 | PMG Research Of Hickory, LLC | Hickory | North Carolina | United States | 28602 |
576 | Peters Medical Research | High Point | North Carolina | United States | 27262 |
577 | Research Institute of the Carolinas, PLLC | Mooresville | North Carolina | United States | 28117 |
578 | Crystal Coast Family Practice | Morehead City | North Carolina | United States | 28557 |
579 | Burke Primary Care | Morganton | North Carolina | United States | 28655 |
580 | Pinehurst Medical Clinic, Inc. | Pinehurst | North Carolina | United States | 28374 |
581 | Pinehurst Medical Clinic. Inc. | Pinehurst | North Carolina | United States | 28374 |
582 | Blue Ridge Family Physicians, PPLC | Raleigh | North Carolina | United States | 27607 |
583 | PMG Research of Raleigh, LLC | Raleigh | North Carolina | United States | 27609 |
584 | Wake Internal Medicine Consultants, Inc. | Raleigh | North Carolina | United States | 27612 |
585 | Wake Research Associates, LLC | Raleigh | North Carolina | United States | 27612 |
586 | Boice-Willis Clinic | Rocky Mount | North Carolina | United States | 27804 |
587 | PMG Research of Salisbury | Salisbury | North Carolina | United States | 28144 |
588 | Tabor City Family Medicine | Tabor City | North Carolina | United States | 28463 |
589 | PMG Research of Wilmington | Wilmington | North Carolina | United States | 28401 |
590 | PMG Research Wilmington Research Associates | Wilmington | North Carolina | United States | 28401 |
591 | Natalie A. Doyle, MD PA | Wilson | North Carolina | United States | 27893 |
592 | Ardmore Family Practice | Winston-Salem | North Carolina | United States | 27103 |
593 | Clinical Trials of America, Inc. | Winston-Salem | North Carolina | United States | 27103 |
594 | Clinical Trials of America, inc | Winston-Salem | North Carolina | United States | 27103 |
595 | PMG Research of Winston-Salem | Winston-Salem | North Carolina | United States | 27103 |
596 | Winston-Salem Health Care | Winston-Salem | North Carolina | United States | 27103 |
597 | Plains Clinical Research Center | Fargo | North Dakota | United States | 58104 |
598 | Daystar Clinical Research | Akron | Ohio | United States | 44313 |
599 | CFP Research, Inc. | Cincinnati | Ohio | United States | 45242 |
600 | Rapid Medical Research, Inc. | Cleveland | Ohio | United States | 44122 |
601 | Cleveland Clinic | Cleveland | Ohio | United States | 44195 |
602 | The Ohio State University | Columbus | Ohio | United States | 43210-1228 |
603 | Feldman Family Practice | Columbus | Ohio | United States | 43213 |
604 | MidWest Cardiology Research Foundation | Columbus | Ohio | United States | 43214 |
605 | Riverside Methodist Hospital | Columbus | Ohio | United States | 43214 |
606 | Remington-Davis Incorporated | Columbus | Ohio | United States | 43215 |
607 | Midtowne Family Practice Centre | Columbus | Ohio | United States | 43228 |
608 | PriMed Clinical Research | Dayton | Ohio | United States | 45419 |
609 | HWC Women's Research Center | Englewood | Ohio | United States | 45322 |
610 | Cleveland Clinic Fairview Cardiovascular Medicine | Fairview Park | Ohio | United States | 44126 |
611 | Prestige Clinical Research | Franklin | Ohio | United States | 45005 |
612 | TriPhase Research, Ltd. | Franklin | Ohio | United States | 45005 |
613 | Holzer Clinic, Inc | Gallipolis | Ohio | United States | 45631 |
614 | Office of Dr. Saleem Khan, MD, Inc | London | Ohio | United States | 43140 |
615 | North Central Research | Mansfield | Ohio | United States | 44903 |
616 | OhioHealth Research Institute | Mansfield | Ohio | United States | 44903 |
617 | R&R Research-Smith Clinic | Marion | Ohio | United States | 43302 |
618 | David R. Mandel, MD, Inc | Mayfield | Ohio | United States | 44143 |
619 | Paramount Medical Research and Consulting, LLC | Middleburg Heights | Ohio | United States | 44130 |
620 | Newark Physician Associates | Newark | Ohio | United States | 43055 |
621 | Family Medicine and Occupational Health Center, Inc. | Shaker Heights | Ohio | United States | 44120 |
622 | Abner Cordero, M.D. | Tiffin | Ohio | United States | 44883 |
623 | Arthritis Associates of Northwest Ohio, Inc. | Toledo | Ohio | United States | 43606 |
624 | Mercy St Vincent Medical Center | Toledo | Ohio | United States | 43608 |
625 | Toledo Cardiology Consultants c/o Cardiac Research | Toledo | Ohio | United States | 43608 |
626 | South Toledo Internists | Toledo | Ohio | United States | 43614 |
627 | University of Toledo Health Science Campus | Toledo | Ohio | United States | 43614 |
628 | UT Medical Center Medicine Clinic | Toledo | Ohio | United States | 43614 |
629 | Trenton Family Medicine | Trenton | Ohio | United States | 45067 |
630 | Lake Medical Research, LLC | Willoughby Hills | Ohio | United States | 44094 |
631 | Pharmacotherapy Research Associates Incorporated | Zanesville | Ohio | United States | 43701 |
632 | LION Research | Norman | Oklahoma | United States | 73069 |
633 | Integris Physicians Services | Oklahoma City | Oklahoma | United States | 73109 |
634 | Integris Cardiovascular Physicians LLC | Oklahoma City | Oklahoma | United States | 73112 |
635 | Integris Family Care Central | Oklahoma City | Oklahoma | United States | 73112 |
636 | Integris Physician Services | Oklahoma City | Oklahoma | United States | 73112 |
637 | Lynn Health Science Institute | Oklahoma City | Oklahoma | United States | 73112 |
638 | Healthcare Research Consultants | Tulsa | Oklahoma | United States | 74135 |
639 | Integrated Medical Research, PC | Ashland | Oregon | United States | 97520 |
640 | Lane Medical Research Group | Eugene | Oregon | United States | 97401 |
641 | Oregon Medical Group Adult Medicine Clinic | Eugene | Oregon | United States | 97401 |
642 | Oregon Medical Group Clinical Research | Eugene | Oregon | United States | 97401 |
643 | Institute of Diabetes and Endocrinology | Medford | Oregon | United States | 97501 |
644 | Rogue Valley Physicians-Clinical Research Group | Medford | Oregon | United States | 97504 |
645 | Fanno Creek Clinic | Portland | Oregon | United States | 97219-1940 |
646 | Affinity Research | Portland | Oregon | United States | 97219 |
647 | Portland Rheumatology Clinic, LLC | Portland | Oregon | United States | 97219 |
648 | Internal Medicine Research | Portland | Oregon | United States | 97225 |
649 | University Orthopedics Center | Altoona | Pennsylvania | United States | 16602 |
650 | Tri-State Medical Group | Beaver | Pennsylvania | United States | 15009 |
651 | East Penn Rheumatology Associates, PC | Bethlehem | Pennsylvania | United States | 18015 |
652 | Buckingham Family Medicine | Buckingham | Pennsylvania | United States | 18912 |
653 | Camp Hill Clinical Research Center | Camp Hill | Pennsylvania | United States | 17011 |
654 | Butler Medical Associates | Chicora | Pennsylvania | United States | 16025 |
655 | Perkiomen Valley Family Practice, PC | Collegeville | Pennsylvania | United States | 19426-3626 |
656 | Rheumatology Associates, Ltd | Colmar | Pennsylvania | United States | 18915 |
657 | Office of J. Miller Oppy, MD, Youghiogheny Primary Care Practice | Connellsville | Pennsylvania | United States | 15425 |
658 | Brandywine Clinical Research | Downingtown | Pennsylvania | United States | 19335 |
659 | Altoona Center for Clinical Research | Duncansville | Pennsylvania | United States | 16635 |
660 | Saint Vincent Consultant in Cardiovascular Diseases, LLC | Erie | Pennsylvania | United States | 16502 |
661 | Arthritis Associates | Erie | Pennsylvania | United States | 16508 |
662 | Center for Assessment and Research of Erie | Erie | Pennsylvania | United States | 16508 |
663 | Stan F. Slabic, M.D. | Erie | Pennsylvania | United States | 16509 |
664 | AMH Feasterville Family HealthCare Center | Feasterville | Pennsylvania | United States | 19053 |
665 | Westmoreland Neurology Associates, Incorporated | Greensburg | Pennsylvania | United States | 15601 |
666 | Harleysville Medical Assoc | Harleysville | Pennsylvania | United States | 19438-2513 |
667 | Lederach Family Medicine | Harleysville | Pennsylvania | United States | 19438 |
668 | Dr. Bruce Morrison, Family Practice | Huntingdon Valley | Pennsylvania | United States | 19006 |
669 | Detweiler Family Medicine and Associates, PC | Lansdale | Pennsylvania | United States | 19446 |
670 | Green and Seidner Family Practice Associates | Lansdale | Pennsylvania | United States | 19446 |
671 | Lansdale Medical Group Family Practice | Lansdale | Pennsylvania | United States | 19446 |
672 | Bucks County Clinical Research | Morrisville | Pennsylvania | United States | 19067-5008 |
673 | Pearl Clinical Research, Inc. | Norristown | Pennsylvania | United States | 19401 |
674 | Lehigh Wellness Center Outpatient Services | Philadelphia | Pennsylvania | United States | 19126 |
675 | Founders Research Corporation | Philadelphia | Pennsylvania | United States | 19152 |
676 | VA Pittsburgh Healthcare System | Pittsburgh | Pennsylvania | United States | 15206 |
677 | VA Pittsburgh Healthcare System | Pittsburgh | Pennsylvania | United States | 15240 |
678 | Dairyland Medical Center | Red Lion | Pennsylvania | United States | 17356 |
679 | Sfm Clinical Trials, PC | Scotland | Pennsylvania | United States | 17254 |
680 | Elite Medical Research, Inc. | Sellersville | Pennsylvania | United States | 18960 |
681 | Prime Health Network | Springfield | Pennsylvania | United States | 19064 |
682 | University Orthopedics Center | State College | Pennsylvania | United States | 16801 |
683 | The Office of Dr. Joseph T. Morelli, DO | Stoneboro | Pennsylvania | United States | 16153 |
684 | Tipton Medical and Diagnostic Center | Tipton | Pennsylvania | United States | 16684 |
685 | Pish Medical Associates | Uniontown | Pennsylvania | United States | 15401 |
686 | PEAK Research, LLC | Upper Saint Clair | Pennsylvania | United States | 15241 |
687 | Allegheny Rheumatology - WPAHS - ASRI | Wexford | Pennsylvania | United States | 15090 |
688 | Clinical Research Center of Reading, LLC | Wyomissing | Pennsylvania | United States | 19610 |
689 | Cardiology Consultants of Philadelphia | Yardley | Pennsylvania | United States | 19067 |
690 | Jeffry A. Lindenbaum DO, PC | Yardley | Pennsylvania | United States | 19067 |
691 | New England Center for Clinical Research | Cranston | Rhode Island | United States | 02920 |
692 | Partners in Clinical Research | Cumberland | Rhode Island | United States | 02864 |
693 | Hugo M. Yamada, MD | Lincoln | Rhode Island | United States | 02865 |
694 | Rheumatology Associates | Pawtucket | Rhode Island | United States | 02860 |
695 | Medical Office Center | Providence | Rhode Island | United States | 02905 |
696 | Anderson Heart | Anderson | South Carolina | United States | 29621 |
697 | AnMed Health | Anderson | South Carolina | United States | 29621 |
698 | Low Country Rheumatology, PA/Low Country Research Center | Charleston | South Carolina | United States | 29406-9333 |
699 | Clinical Trials of South Carolina | Charleston | South Carolina | United States | 29406 |
700 | St. Andrews Medical | Charleston | South Carolina | United States | 29407 |
701 | Neem Research Group Inc. | Columbia | South Carolina | United States | 29201 |
702 | Columbia Arthritis Center Pa | Columbia | South Carolina | United States | 29204 |
703 | MedTrial | Columbia | South Carolina | United States | 29204 |
704 | Clinical Research Associates, LLC | Florence | South Carolina | United States | 29501 |
705 | Palmetto Clinical Trial Services, LLC | Greenville | South Carolina | United States | 29601 |
706 | Paris View Family Practice | Greenville | South Carolina | United States | 29601 |
707 | John Milas | Greer | South Carolina | United States | 29650 |
708 | Radiant Research, Inc | Greer | South Carolina | United States | 29650 |
709 | DeGarmo Institute of Medical Research | Greer | South Carolina | United States | 29651 |
710 | Mountain View Clinical Research, Inc. | Greer | South Carolina | United States | 29651 |
711 | Palmetto Clinical Trial Services, LLC at the Family Healthcare Center | Laurens | South Carolina | United States | 29360 |
712 | Berkeley Medical Center | Moncks Corner | South Carolina | United States | 29461 |
713 | PMG Research of Charleston | Mount Pleasant | South Carolina | United States | 29464 |
714 | North Myrtle Beach Family Practice | North Myrtle Beach | South Carolina | United States | 29582 |
715 | Coulter Clinic | Orangeburg | South Carolina | United States | 29115-4931 |
716 | Orangeburg Medical Associates, PA | Orangeburg | South Carolina | United States | 29118 |
717 | The Carolina Center for Rheumatology & Arthritis Care, PA | Rock Hill | South Carolina | United States | 29732 |
718 | Hillcrest Clinical Research, LLC | Simpsonville | South Carolina | United States | 29681 |
719 | Hillcrest Family Practice | Simpsonville | South Carolina | United States | 29681 |
720 | Palmetto Research | Spartanburg | South Carolina | United States | 29302 |
721 | Palmetto Clinical Research | Summerville | South Carolina | United States | 29485 |
722 | Southeastern Research Associates, Inc. | Taylors | South Carolina | United States | 29687 |
723 | Odyssey Research/Sanford Clinic - Aberdeen | Aberdeen | South Dakota | United States | 57401 |
724 | Sanford Clinic - Aberdeen | Aberdeen | South Dakota | United States | 57401 |
725 | Regional Health Clinic Research | Rapid City | South Dakota | United States | 57701 |
726 | Regional Medical Clinic-Rheumatology | Rapid City | South Dakota | United States | 57701 |
727 | Health Concepts | Rapid City | South Dakota | United States | 57702 |
728 | Brown Clinic PLLP | Watertown | South Dakota | United States | 57201 |
729 | Odyssey Research | Watertown | South Dakota | United States | 57201 |
730 | Holston Medical Group | Bristol | Tennessee | United States | 37620 |
731 | Internal Medicine & Pediatric Associates of Bristol | Bristol | Tennessee | United States | 37620 |
732 | PMG Research of Bristol | Bristol | Tennessee | United States | 37620 |
733 | Parkway Medical Group | Fayetteville | Tennessee | United States | 37334 |
734 | Stern Cardiovascular Foundation, inc. | Germantown | Tennessee | United States | 38138 |
735 | Arthritis Clinic | Jackson | Tennessee | United States | 38305 |
736 | The Jackson Clinic, PA | Jackson | Tennessee | United States | 38305 |
737 | State of Franklin Healthcare Associates Clinical Research | Johnson City | Tennessee | United States | 37604 |
738 | Holston Medical Group | Kingsport | Tennessee | United States | 37660 |
739 | Holston Valley Surgery Center | Kingsport | Tennessee | United States | 37660 |
740 | Gupta, Ramesh C MD | Memphis | Tennessee | United States | 38119-5214 |
741 | Access Clinical Trials, Inc. | Nashville | Tennessee | United States | 37203 |
742 | Premier Orthopaedics | Nashville | Tennessee | United States | 37203 |
743 | The Cholesterol Center of Nashville | Nashville | Tennessee | United States | 37203 |
744 | Nashville Medical Research Institute | Nashville | Tennessee | United States | 37205 |
745 | Quality Medical Research | Nashville | Tennessee | United States | 37211 |
746 | Amarillo Medical Specialists, LLP | Amarillo | Texas | United States | 79106 |
747 | Pharma Tex Research, LLC | Amarillo | Texas | United States | 79106 |
748 | Family Health Care Association | Arlington | Texas | United States | 76013 |
749 | South Arlington Primary Care Associates PA | Arlington | Texas | United States | 76017 |
750 | DCT - Anchor, LLC dba Discovery Clinical Trials | Arlington | Texas | United States | 76018 |
751 | DCT-AACT, LLC dba Discovery Clinical Trials | Austin | Texas | United States | 78758 |
752 | Southeast Texas Cardiology Associates | Beaumont | Texas | United States | 77702 |
753 | Southeast Texas Clinical Research Center | Beaumont | Texas | United States | 77702 |
754 | Kaner Medical Group PA | Bedford | Texas | United States | 76021 |
755 | Nexxus Research Group, LLC | Bedford | Texas | United States | 76021 |
756 | Texas Orthopedic Specialists, PLLC | Bedford | Texas | United States | 76021 |
757 | MedicalEdge Healthcare Group, PA, dba Leading Edge Research, PA | Carrollton | Texas | United States | 75007 |
758 | Prentiss Family Medicine | Colleyville | Texas | United States | 76034 |
759 | Carlos B. Everett, MD | Corpus Christi | Texas | United States | 78405 |
760 | Discovery Clinical Research | Corpus Christi | Texas | United States | 78411 |
761 | Texas Health Physicians Group | Dallas | Texas | United States | 75220 |
762 | Soltero Cardiovascular Research Center/Baylor University Medical Center | Dallas | Texas | United States | 75226 |
763 | Arthritis Care and Diagnostic Center, P.A. | Dallas | Texas | United States | 75231 |
764 | Medical Specialists Associated | Dallas | Texas | United States | 75231 |
765 | Metroplex Clinical Research Center | Dallas | Texas | United States | 75231 |
766 | SouthWest Rheumatology, P.A. | Dallas | Texas | United States | 75231 |
767 | DCT - Genesis Neighborhood Research, LLC dba Discovery Clinical Trials | Dallas | Texas | United States | 75254 |
768 | Rajendra K. Marwah, MD | El Paso | Texas | United States | 79902 |
769 | Kaner Medical Group, PA | Euless | Texas | United States | 76039 |
770 | The Medical Group of Texas | Fort Worth | Texas | United States | 76104 |
771 | Texas Health Physicians Group | Fort Worth | Texas | United States | 76107 |
772 | T & R Clinic, P. A. | Fort Worth | Texas | United States | 76117 |
773 | Rheumatology-UTMB | Galveston | Texas | United States | 77555 |
774 | Towngate Plaza Medical Center | Garland | Texas | United States | 75041 |
775 | ProCare Clinical Trials | Grand Prairie | Texas | United States | 75052 |
776 | The Office of Amer Zaheer MD, PA | Houston | Texas | United States | 77004 |
777 | Salim Gopalani, MD, PA | Houston | Texas | United States | 77008 |
778 | Office of Cyril Wolf, MD | Houston | Texas | United States | 77024 |
779 | Village Family Practice | Houston | Texas | United States | 77024 |
780 | Kelsey Seybold Clinic | Houston | Texas | United States | 77025-1669 |
781 | Oxford Clinical Research, LLC | Houston | Texas | United States | 77074 |
782 | MCA Research | Houston | Texas | United States | 77079 |
783 | Texas Health Physicians Group | Irving | Texas | United States | 75039 |
784 | One World Medical Associates, P.A. | Lewisville | Texas | United States | 75057 |
785 | Pri-Med Care | Lewisville | Texas | United States | 75067 |
786 | South Texas Institute of Health | McAllen | Texas | United States | 78501 |
787 | DCT - Genesis Seidmeyer Research, LLC dba Discovery Clinical Trials | McKinney | Texas | United States | 75071 |
788 | Southwest Rheumatology, PA | Mesquite | Texas | United States | 75150 |
789 | Midland Clinical Research Center | Midland | Texas | United States | 79707 |
790 | Basin Orthopedics Surgical Specialists | Odessa | Texas | United States | 79761 |
791 | Center for Hypertension and Internal Medicine | Odessa | Texas | United States | 79761 |
792 | Odessa Heart Institute | Odessa | Texas | United States | 79761 |
793 | Permian Research Foundation | Odessa | Texas | United States | 79761 |
794 | Office of David K. McDonald, M.D.. P.A. | Pasadena | Texas | United States | 77504 |
795 | Centex Studies, Inc. | Pharr | Texas | United States | 78577-5198 |
796 | Clinical Investigations of Texas, LLC | Plano | Texas | United States | 75075 |
797 | DCT-Genesis naini, LLC dba Discovery Clinical Trials | Plano | Texas | United States | 75075 |
798 | North Texas Medical Research | Plano | Texas | United States | 75093 |
799 | MedicalEdge Healthcare Group, PA | Richardson | Texas | United States | 75080 |
800 | Texas Health Physicians Group | Richardson | Texas | United States | 75080 |
801 | Ivan N. Mefford, MD, PhD, PA | Richmond | Texas | United States | 77469 |
802 | Paragon Research Center, LLC | San Antonio | Texas | United States | 78205 |
803 | Quality Assurance Research Center | San Antonio | Texas | United States | 78207 |
804 | Quality Research Inc. | San Antonio | Texas | United States | 78209 |
805 | Physician PrimeCare Research Institute, PLLC dba Health Texas Research Institute | San Antonio | Texas | United States | 78212 |
806 | GSA Research | San Antonio | Texas | United States | 78213 |
807 | Sun Research Institute | San Antonio | Texas | United States | 78215 |
808 | Radiant Research San Antonio Northeast | San Antonio | Texas | United States | 78217 |
809 | Briggs Clinical Research, LLC | San Antonio | Texas | United States | 78224 |
810 | DCT - Barlite, LLC dba Discovery Clinical Trials | San Antonio | Texas | United States | 78224 |
811 | S.A.M. Clinical Research Center | San Antonio | Texas | United States | 78229 |
812 | WellMed Clinical Research | San Antonio | Texas | United States | 78229 |
813 | DCT-Westover Hills, LLC dba Discovery Clinical Trials | San Antonio | Texas | United States | 78251 |
814 | DCT - Stone Oak, LLC dba Discovery Clinical Trials | San Antonio | Texas | United States | 78258 |
815 | The Office of Shahbaz Yazdani, MD, PA | San Antonio | Texas | United States | 78258 |
816 | Southlake Clinical Trials | Southlake | Texas | United States | 76092 |
817 | Sugar Land Med-Ped Clinic, PA | Sugar Land | Texas | United States | 77479 |
818 | Crossroads Clinical Research, LLC | Victoria | Texas | United States | 77901 |
819 | Crossroads Clinical Research | Victoria | Texas | United States | 77901 |
820 | Office of Pamela Dugano-Daphnis | Webster | Texas | United States | 77598 |
821 | Advanced Research Institute | Ogden | Utah | United States | 84405 |
822 | Advanced Clinical Research | West Jordan | Utah | United States | 84088 |
823 | Burke Internal Medicine & Research | Burke | Virginia | United States | 22015 |
824 | Burke Internal Medicine | Burke | Virginia | United States | 22015 |
825 | Center for Arthritis and Rheumatic Diseases | Chesapeake | Virginia | United States | 23320-4985 |
826 | Bayview Physicians oa Cardiovascular Associates, Ltd | Chesapeake | Virginia | United States | 23320 |
827 | David Ramstad, MD, MPH and Associates | Chesapeake | Virginia | United States | 23320 |
828 | Danville Internal Medicine, Inc. | Danville | Virginia | United States | 24541 |
829 | Danville Orthopedic Clinic | Danville | Virginia | United States | 24541 |
830 | Seven Corners Medical Research Center | Falls Church | Virginia | United States | 22044 |
831 | Hampton Family Practice | Hampton | Virginia | United States | 23666 |
832 | Manassas Clinical Research Center | Manassas | Virginia | United States | 20110 |
833 | Bruton Avenue Family Practice | Newport News | Virginia | United States | 23601 |
834 | Internal Medicine Kidney and Hypertension Center | Norfolk | Virginia | United States | 23502 |
835 | National Clinical Research - Norfolk Inc. | Norfolk | Virginia | United States | 23502 |
836 | Sentara Medical Group | Norfolk | Virginia | United States | 23502 |
837 | Ettrick Health Center | Petersburg | Virginia | United States | 23803 |
838 | Arthritis and Rheumatic Research | Portsmouth | Virginia | United States | 23701 |
839 | Roanoke Heart Institute | Roanoke | Virginia | United States | 24014 |
840 | Harbourview Professional Center | Suffolk | Virginia | United States | 23435 |
841 | Chase Research Group, LLC | Virginia Beach | Virginia | United States | 23452 |
842 | The Center for Excellence in Aging and Geriatric Health | Williamsburg | Virginia | United States | 23185 |
843 | Highline Medical Center Laboratory | Burien | Washington | United States | 98166 |
844 | Puget Sound Osteoporosis Center | Seattle | Washington | United States | 98144 |
845 | Arthritis Northwest | Seattle | Washington | United States | 98166-2967 |
846 | Arthritis Northwest Rheumatology | Spokane | Washington | United States | 99204 |
847 | Lawrence S. Eastburn, MD, PS | Spokane | Washington | United States | 99204 |
848 | Pulmonary and Research Associates | Spokane | Washington | United States | 99204 |
849 | The Office of William Gray, Md, Family Practice | Spokane | Washington | United States | 99216 |
850 | John F. Long, D.O. | Spokane | Washington | United States | 99218 |
851 | George H. Krick, MD | Tacoma | Washington | United States | 98405 |
852 | Northwest Family and Spinal Clinic | Tacoma | Washington | United States | 98405 |
853 | Rheumatology Infusion Services | Tacoma | Washington | United States | 98405 |
854 | Tacoma Center for Arthritis Research, PS | Tacoma | Washington | United States | 98405 |
855 | Wenatchee Valley Medical Center, Research Department | Wenatchee | Washington | United States | 98801 |
856 | Clinical Trials Northwest | Yakima | Washington | United States | 98902 |
857 | Rheumatology and Pulmonary Clinic | Beckley | West Virginia | United States | 25801 |
858 | Mountain State Clinical Research | Clarksburg | West Virginia | United States | 26301 |
859 | University Cardiovascular Services. Robert C. Byrd Clinical Center | Huntington | West Virginia | United States | 25701 |
860 | WVVA Healthcare Alliance | Lewisburg | West Virginia | United States | 24901 |
861 | Parkersburg Cardiology Associates | Parkersburg | West Virginia | United States | 26101 |
862 | Meriter Medical Group | Madison | Wisconsin | United States | 53713 |
863 | University of Wisconsin School of Medicine and Public Health | Madison | Wisconsin | United States | 53715 |
864 | UW Health Physicians | Madison | Wisconsin | United States | 53715 |
865 | St. Lukes Pain Management Center | Milwaukee | Wisconsin | United States | 53215 |
866 | Zablocki VA Medical Center | Milwaukee | Wisconsin | United States | 53295 |
867 | Aspirus Cardiovascular Associates - Rhinelander | Rhinelander | Wisconsin | United States | 54501 |
868 | Aspirus Cardiovascular Associates | Wausau | Wisconsin | United States | 54401 |
869 | Aspirus Heart & Vascular lnstitute--Research & Education) | Wausau | Wisconsin | United States | 54401 |
870 | Aspirus Wausau Hospital | Wausau | Wisconsin | United States | 54401 |
871 | Allegiance Research Specialists, LLC | Wauwatosa | Wisconsin | United States | 53226 |
872 | Hunter Clinical Research | Broadmeadow | New South Wales | Australia | 2292 |
873 | Wesley Medical Centre | Auchenflower | Queensland | Australia | 4066 |
874 | Australian Clinical Research Organisation | Caboolture | Queensland | Australia | 4510 |
875 | Rheumatology Department | Cairns | Queensland | Australia | 4870 |
876 | AusTrials Pty Ltd | Kippa Ring | Queensland | Australia | 4021 |
877 | Core Research Group | Milton | Queensland | Australia | 4064 |
878 | AusTrials Pty Ltd | Sherwood | Queensland | Australia | 4075 |
879 | Monash Medical Centre, Department of Rheumatology | Clayton | Victoria | Australia | 3168 |
880 | Rheumatology Department | Heidelberg West | Victoria | Australia | 3081 |
881 | Emeritus Research | Malvern East | Victoria | Australia | 3145 |
882 | The Goatcher Clinical Research Unit | Shenton Park | Western Australia | Australia | 6008 |
883 | The Colin Bayliss Research and Teaching Unit | Victoria Park | Western Australia | Australia | 6979 |
884 | CLINCOR - Clinica de Exames Cardiologicos e Ecografia S/C Ltda | Maceio | AL | Brazil | 57021-500 |
885 | Hospital do Coracao de Alagoas | Maceio | AL | Brazil | 57052-580 |
886 | CIP - Centro Internacional de Pesquisas | Goiania | GO | Brazil | 74110-120 |
887 | Via Medica - Centro Clinico | Goiania | GO | Brazil | 74223-130 |
888 | CMIP - Centro Mineiro de Pesquisa | Juiz de Fora | MG | Brazil | 36010-570 |
889 | Hopsital das Clinicas da Universidade Federal de Minas Gerais | Belo Horizonte | Minas Gerais | Brazil | 30150-260 |
890 | Hospital e Maternidade Angelina Caron, Sala Pesquisa Clinica | Campina Grande do Sul | PR | Brazil | 83430-000 |
891 | CEPEME-CERHFAC Centro de Estudos e Pesquisas Medicas | Curitiba | PR | Brazil | 80030-220 |
892 | Centro de Estudos do Hospital de ClÃnicas da UFPR | Curitiba | PR | Brazil | 80060-240 |
893 | Hospital Universitário Clementino Fraga Filho - UFRJ | Rio de Janeiro | RJ | Brazil | 21941-913 |
894 | CCBR Brasil Centro de Pesquisas e Analises Clinicas Ltda | Rio de Janeiro | RJ | Brazil | 22271-100 |
895 | Hospital Ipanema Plus | Rio de Janeiro | RJ | Brazil | 22411-001 |
896 | Clinica de Reumatologia do Centro Médico BarraShopping | Rio de Janeiro | RJ | Brazil | 22649-900 |
897 | Centro de Pesquisa Clinica | Porto Alegre | RS | Brazil | 90035-903 |
898 | Associação Hospitalar Moinhos de Vento (AHMV) / CMIC | Porto Alegre | RS | Brazil | 90560-030 |
899 | Hospital São Lucas - Pontificia | Porto Alegre | RS | Brazil | 90610-000 |
900 | Hospital e Maternidade Celso Pierro - Puc Campinas | Campinas | SAO Paulo | Brazil | 13059-740 |
901 | Centro de Ensino e Pesquisa Hospital Sao Lucas | Aracaju | SE | Brazil | 49015-400 |
902 | PUC Campinas | Campinas | SP | Brazil | 13059-740 |
903 | Hospital das Clinicas da UNICAMP | Campinas | SP | Brazil | 13083-888 |
904 | Hospital das Clinicas da Faculdade de Medicina de Marilia | Marilia | SP | Brazil | 17519-030 |
905 | Hospital de Base - Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto | Sao Jose do Rio Preto | SP | Brazil | 15090-000 |
906 | Hospital Alemao Oswaldo Cruz | Sao Paulo | SP | Brazil | 01323-903 |
907 | Setor de Lip., Arterosc. e BioVasc. - Disc. de Cardiologia | Sao Paulo | SP | Brazil | 04039-030 |
908 | CEPIC - Centro Paulista de Investigacao ClÃnica | Sao Paulo | SP | Brazil | 04266-010 |
909 | IMA Brasil - Instituto de Medicina Avancada | Sao Paulo | SP | Brazil | 05437-010 |
910 | CPCLIN - Centro de Pesquisas ClÃnicas | São Paulo | SP | Brazil | 01244-030 |
911 | Hospital Sao Salvador - Medicos Reunidos Ltda. | Goiania-GO | Brazil | 74110-020 | |
912 | Ambulatorio de Especialidades Mario Covas | Marilia/SP | Brazil | 17519-000 | |
913 | Hospital Nossa Senhora da Conceicao | Porto Alegre, RS | Brazil | 91350-200 | |
914 | Hospital das Clinicas da UFPE | Recife - Pernambuco | Brazil | 52679-420 | |
915 | Hospital Dos Servidores Do Estado do Rio de Janeiro | Rio de Janeiro | Brazil | 20221-903 | |
916 | Faculdade de Medicina DO ABC | Santo Andre | Brazil | 09060-650 | |
917 | South Calgary Medical Clinic - Sunpark Professional Center | Calgary | Alberta | Canada | T2X 3X7 |
918 | Allin Clinic | Edmonton | Alberta | Canada | T5K 2A2 |
919 | Dr. MPJ Senaratne Professional Corporation | Edmonton | Alberta | Canada | T6K 4C1 |
920 | Medical Arts Health Research Group | Kelowna | British Columbia | Canada | V1Y 3G8 |
921 | The Medical Arts Health Research Group | Penticton | British Columbia | Canada | V2A 5C8 |
922 | Ocean West Research Clinic Inc. | Surrey | British Columbia | Canada | V3S 2N6 |
923 | Prohealth Clinical Research Inc. | Vancouver | British Columbia | Canada | V5Z 4E1 |
924 | Office of Dr. Milton F. Baker | Victoria | British Columbia | Canada | V8P 5P6 |
925 | The Medical Arts Health Research Group | West Vancouver | British Columbia | Canada | V7T 2Z3 |
926 | Rivergrove Medical Clinic | Winnipeg | Manitoba | Canada | R2V 4W3 |
927 | Manitoba Clinic | Winnipeg | Manitoba | Canada | R3A 1M3 |
928 | G.A. Research Associates Ltd/Ltee | Moncton | New Brunswick | Canada | E1G 1A7 |
929 | Eric N. Grant Professional Corporation | Quispamis | New Brunswick | Canada | E2E 4J8 |
930 | Office of Dr. Brian N. Craig | Saint John | New Brunswick | Canada | E2K 2T8 |
931 | Commonwealth Medical Clinic | Mount Pearl | Newfoundland and Labrador | Canada | A1N 1W7 |
932 | Paradise Medical Clinic | Paradise | Newfoundland and Labrador | Canada | A1L 1C6 |
933 | White Hills Medical Clinic | St. John's | Newfoundland and Labrador | Canada | A1A 3R5 |
934 | Nexus Clinic Research | St. John's | Newfoundland and Labrador | Canada | A1A 5E8 |
935 | The Clinical Trials Centre | St. John's | Newfoundland and Labrador | Canada | A1C 2H5 |
936 | Topsail Road Medical Clinic | St. John's | Newfoundland and Labrador | Canada | A1E 2E2 |
937 | MSHJ Research Associates, Inc. | Halifax | Nova Scotia | Canada | B3K 0A4 |
938 | Colchester Research Group | Truro | Nova Scotia | Canada | B2N 1L2 |
939 | Office of Dr. Rohit Nagpal | Brampton | Ontario | Canada | L6R 3A5 |
940 | Aggarwal and Associates Ltd. | Brampton | Ontario | Canada | L6T 3J1 |
941 | Aviva Clinical Trial Group Inc. | Burlington | Ontario | Canada | L7M 4Y1 |
942 | Corunna Medical Research Center | Corunna | Ontario | Canada | N0N 1G0 |
943 | C & L Research | Fort Erie | Ontario | Canada | L2A 1Z3 |
944 | Office of Dr. Jonathan D. Adachi | Hamilton | Ontario | Canada | L8N 1Y2 |
945 | Office of Dr. John Mutrie | Kitchener | Ontario | Canada | N2E 4H9 |
946 | KW Musculoskeletal Research Inc. | Kitchener | Ontario | Canada | N2M 5N6 |
947 | East London Medical Centre | London | Ontario | Canada | N5W 3C6 |
948 | London East Medical Centre | London | Ontario | Canada | N5W 6A2 |
949 | Office of Dr. Gordon Schacter | London | Ontario | Canada | N5Y 5K7 |
950 | Office of Dr. William Blake Bowler | London | Ontario | Canada | N6A 3H5 |
951 | Office of Dr. Robert G. Luton | London | Ontario | Canada | N6A 5G6 |
952 | Malton Medical Centre | Mississauga | Ontario | Canada | L4T 4J2 |
953 | The Arthritis Program Research Group Inc. | Newmarket | Ontario | Canada | L3Y 3R7 |
954 | SKDS Research Inc. | Newmarket | Ontario | Canada | L3Y 5G8 |
955 | Office of Dr. Azim M. Velji | Niagara Falls | Ontario | Canada | L2E 7H1 |
956 | AIM Health Group Trainyards Health and Wellness Centre | Ottawa | Ontario | Canada | K1G 0Z3 |
957 | London Road Diagnostic Clinic & Medical Center | Sarnia | Ontario | Canada | N7T 4X3 |
958 | London Road Diagnostic Clinic & Medical Centre | Sarnia | Ontario | Canada | N7T 4X3 |
959 | Office of Dr. Swaran K. Syan | Sudbury | Ontario | Canada | P3C 5K7 |
960 | Keele Medical Place | Toronto | Ontario | Canada | M3M 3E5 |
961 | Prime Health Clinical Research | Toronto | Ontario | Canada | M4S 1Y2 |
962 | Office of Dr. Ira Bernstein | Toronto | Ontario | Canada | M6A 3B5 |
963 | Office of Dr. Subodh Kanani | Toronto | Ontario | Canada | M8V 3X8 |
964 | Manna Research | Toronto | Ontario | Canada | M9W 4L6 |
965 | North Walkerville Orthopaedic Associates | Windsor | Ontario | Canada | N8W 1E6 |
966 | Research Office | Windsor | Ontario | Canada | N8W 1E6 |
967 | Clinical Research and Arthritis Centre | Windsor | Ontario | Canada | N8X 5A6 |
968 | Centre de sante et de services sociaux de Chicoutimi | Chicoutimi | Quebec | Canada | G7H 5H6 |
969 | ECOGENE-21 / Centre de sante et de services sociaux de Chicoutimi | Chicoutimi | Quebec | Canada | G7H 7P2 |
970 | Clinique de Medicine Familiale de Cowansville | Cowansville | Quebec | Canada | J2K 2X9 |
971 | Centre de recherche clinique Adapra Inc. | L'Ancienne-Lorette | Quebec | Canada | G2E 2X1 |
972 | Centre de Recherche Hochelaga/ Clinique Medicale Hochelaga | Montreal | Quebec | Canada | H1L 2N9 |
973 | Recherche Medicale Appliquee Informatics (AMIR) Inc. | Montreal | Quebec | Canada | H3N 1S4 |
974 | Kells Medical Research Group, Inc. | Pointe-Claire | Quebec | Canada | H9R 4S3 |
975 | Le Manoir de l'Atrium | Quebec City | Quebec | Canada | G1H 7L3 |
976 | Clinique Services Sante Rosemere | Rosemere | Quebec | Canada | J7A 1K7 |
977 | Centre Medical des Carrieres | Saint-Marc-des-Carrieres | Quebec | Canada | G0A 4B0 |
978 | St-Jerome Medical Research Inc. | St-Jerome | Quebec | Canada | J7Z 5T3 |
979 | Centre de Recherche Musculo-Squelettique | Trois-Rivieres | Quebec | Canada | G8Z 1Y2 |
980 | Cardiology and Research | Westmount | Quebec | Canada | H3Z 2M6 |
981 | Downtown Medical Specialists | Saskatoon | Saskatchewan | Canada | S7L 0Y7 |
982 | Recherche Clinique Sigma, Inc. | Quebec | Canada | G1G 3Y8 | |
983 | Institut Universitaire de Cardiologie et de Pneumologie de Québec | Quebec | Canada | G1V 4G5 | |
984 | Hospital Pablo Tobon Uribe - Unidad de Investigaciones | Medellin | Antioquia | Colombia | 050034 |
985 | Reumalab S.A.S. | Medellin | Antioquia | Colombia | 0 |
986 | IPS Rodrigo Botero S.A.S. | Medellin | Antioquia | Colombia | |
987 | Fundacion Cardioinfantil | Bogota | Cundinamarca | Colombia | 0 |
988 | Clinica Colsanitas Sa | Bogota | Cundinamarca | Colombia | |
989 | Fundacion Cardiovascular de Colombia | Floridablanca | Santander | Colombia | |
990 | Fundacion Valle del Lili | Cali | Colombia | 760032 | |
991 | ClÃnica VÃa San Juan | La Union De Tres Rios | Cartago | Costa Rica | 30303 |
992 | Clinica San Agustin | Desamparados Centro | San Jose | Costa Rica | 0000 |
993 | Hospital CIMA San Jose | Escazu | San Jose | Costa Rica | |
994 | Hospital Hotel La Catolica | Goicoechea | San Jose | Costa Rica | |
995 | Consultorio Privado Dr. Alberto Lainez Ventosilla | Moravia | San José | Costa Rica | 0000 |
996 | Centro Medico San Rafael | Alajuela | Costa Rica | ||
997 | Centro de Reumatologia y Osteoporosis | Cartago | Costa Rica | 30101 | |
998 | ClÃnica Garzona | Cartago | Costa Rica | ||
999 | Clinica de Especialidades Medicas Drs. Saenz Castro | Heredia | Costa Rica | ||
1000 | ClÃnica Monte Sión | Heredia | Costa Rica | ||
1001 | ClÃnica San Antonio | Heredia | Costa Rica | ||
1002 | Centro Medico San Jose | San Jose | Costa Rica | ||
1003 | Edificio Panda | San Jose | Costa Rica | ||
1004 | Hospital Clinica Biblica | San Jose | Costa Rica | ||
1005 | Hospital ClÃnica Biblica | San Jose | Costa Rica | ||
1006 | Oficina Privada | San Jose | Costa Rica | ||
1007 | Prince of Wales Hospital | Shatin | NEW Territories | Hong Kong | |
1008 | Centre for Assessment and Treatment of Rheumatic Diseases, Department of Medicine and Geriatrics | New Territories | NT | Hong Kong | |
1009 | Department of Medicine, Queen Mary Hospital | Pokfulam | Hong Kong | ||
1010 | Department of Medicine, North District Hospital | Sheung Shui, NT | Hong Kong | ||
1011 | Centro de Investigacion del Noroeste SC | Tijuana | BAJA California | Mexico | 22010 |
1012 | Comite Mexicano para la Prevencion de la Osteoporosis, A.C. | Mexico | D.f. | Mexico | 06100 |
1013 | Instituto Mexicano de Investigación ClÃnica, S.A. de C.V | Mexico | D.f. | Mexico | 06700 |
1014 | CIF-BIOTEC, Medica Sur | Mexico | DF | Mexico | 14050 |
1015 | Centro Medico Toluca | Metepec | Estado DE Mexico | Mexico | 52140 |
1016 | Hospital Regional ISSSTE | Leon | Guanajuato | Mexico | 37520 |
1017 | Instituto Jalisciense de Investigación ClÃnica SA de CV | Guadalajara | Jalisco | Mexico | 44160 |
1018 | Centro de Estudios de Investigacion Basica y Clinica SC. | Guadalajara | Jalisco | Mexico | 44690 |
1019 | Unidad de Investigacion Dr. Mario Alvizouri Muñoz Ac Del Hospital General Dr. Miguel Silva | Morelia | Michoacan | Mexico | 58000 |
1020 | Hospital Central "Dr. Ignacio Morones Prieto" Unidad Regional de Reumatologia y Osteoporosis | San Luis Potosi | SLP | Mexico | 78240 |
1021 | Clinicos Asociados BOCM, S.C. | Mexico City | Mexico | 03300 | |
1022 | Centro de Investigación Marbella | Panama City | Panama | ||
1023 | IPC - Centro de Salud Integral S.A. | San Isidro | Lima | Peru | L 27 |
1024 | Centro Empresarial - Altavista Polo 4 | Santiago de Surco | Lima | Peru | 00033 |
1025 | Instituto de Ginecologia y Reproducción & Cirugia Minimamente Invasiva | Santiago de Surco | Lima | Peru | 00033 |
1026 | Clinica San Felipe | Lima | Peru | 11 | |
1027 | Centro de Investigaciones Medical | Lima | Peru | L29 | |
1028 | Clinica San Juan Bautista | Lima | Peru | Lima 36 | |
1029 | Mary Mediatrix Medical Center | Lipa City | Batangas | Philippines | 4217 |
1030 | De La Salle Health Sciences Institute | Dasmarinas | Cavite | Philippines | 4114 |
1031 | Chong Hua Hospital | Cebu City | Philippines | 6000 | |
1032 | Southern Philippines Medical Center | Davao City | Philippines | 8000 | |
1033 | Jose R. Reyes Memorial Medical Center | Manila | Philippines | 1003 | |
1034 | Chinese General Hospital and Medical Center | Manila | Philippines | 1014 | |
1035 | Hospital Research Unit, University of Santo Tomas Hospital | Manila | Philippines | 1015 | |
1036 | St. Luke's Medical Center | Quezon City | Philippines | 1102 | |
1037 | Chang Gung Memorial Hospital-Kaohsiung branch, Section of Allergy, Immunology | Nio Sung Township | Kaohsiung County | Taiwan | 833 |
1038 | Tri-Service General Hospital | Neihu District | Taipei CITY | Taiwan | 114 |
1039 | Chang Gung Medical Foundation-Linkou Branch | Gueishan Township | Taoyuan County | Taiwan | 333 |
1040 | Chi-Mei Medical Center | Tainan | Yung Kang | Taiwan | 71004 |
1041 | Buddhist Tzu Chi Dailin General Hospital | Chia-Yi County | Taiwan | 62247 | |
1042 | Chung-Ho Memorial Hospital, Kaoshiung Medical University Hospital | Kaohsiung | Taiwan | 807 | |
1043 | Chung Shan Medical University Hospital | Taichung | Taiwan | 402 | |
1044 | Taichung Veterans General Hospital | Taichung | Taiwan | 40705 | |
1045 | Tri-service General Hospital | Taipei City | Taiwan | 100 | |
1046 | National Taiwan University Hospital | Taipei | Taiwan | 10018 | |
1047 | Taipei Veterans General Hospital | Taipei | Taiwan | 112 | |
1048 | CRI "Clinical Territorial Medical Association "University Clinic", | Simferopol | Crimea | Ukraine | 95017 |
1049 | Municipal Medical Institution "City Clinical Hospital #3", Department of Rheumatology | Chernivtsi | Ukraine | 58022 | |
1050 | MI Dnipropetrovsk Regional Clinical Hospital named after I.I Mechnikov | Dnipropetrovsk | Ukraine | 49005 | |
1051 | State Institution "Dnipropetrovsk Medical Academy of MOH, Ukraine | Dnipropetrovsk | Ukraine | 49005 | |
1052 | Rheumatology Department, MMI "City Clinical Hospital #5", DNMU n.a. M.Gorkyy, | Donetsk | Ukraine | 83001 | |
1053 | Donetsk National Med University, Chair of Propaedeutics and Internal Medicine | Donetsk | Ukraine | 83003 | |
1054 | Municipal Establishment of Health Care | Kharkiv | Ukraine | 61002 | |
1055 | City Clinical Hospital # 8, Dept of Cardiology and Functional Diagnostics | Kharkiv | Ukraine | 61178 | |
1056 | City Clinical Hospital #1 | Kyiv | Ukraine | 02091 | |
1057 | National Scientific Center "The Strazhesko Institute of Cardiology" | Kyiv | Ukraine | 03680 | |
1058 | State Institution "Republican clinical hospital of MOH of Ukraine" | Kyiv | Ukraine | 04053 | |
1059 | Family Medicine Department of NMAPE named after PL Shupyk, | Kyiv | Ukraine | 04107 | |
1060 | Lutsk City Clinical Hospital | Lutsk | Ukraine | 43024 | |
1061 | Municipal City Clinical Hospital #5 | Lviv | Ukraine | 79013 | |
1062 | Center of Reconstructive and Regenerative Medicine (University clinic) of | Odesa | Ukraine | 65009 | |
1063 | Treatment-and-Diagnostic Center LLC "Desna" Ltd | Ternopil | Ukraine | 46010 | |
1064 | Municipal enterprise " City Hospital # 7", | Zaporizhzhia | Ukraine | 69118 | |
1065 | Municipal Institution "Zaporizhzhya City Multiple Discipline Clinical Hospital #9" | Zaporizhzhya | Ukraine | 69065 | |
1066 | Zhytomyr Regional Clinical Hospital n.a. O.F. Gerbachevs'kyy/ Rheumatology Center | Zhytomyr | Ukraine | 10003 |
Sponsors and Collaborators
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- The Cleveland Clinic
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- A3191172
- 2004-002441-13
- PRECISION TRIAL
Study Results
Participant Flow
Recruitment Details | The study was conducted at 950 centers in Australia (11), Brazil (30), Canada (64), Colombia (7), Costa Rica (12), Hong Kong (4), Mexico (11), Panama (2), Peru (5), Philippines (8), Taiwan (10), Ukraine 19), and United States (767); a total of 24 sites were activated but did not randomized any subject. |
---|---|
Pre-assignment Detail | All eligible participants were enrolled in to the study. |
Arm/Group Title | Celecoxib | Ibuprofen | Naproxen |
---|---|---|---|
Arm/Group Description | Celecoxib 100-200 mg twice daily with placebo to match ibuprofen 600-800 mg thrice daily and placebo to match naproxen 375-500 mg twice daily | Ibuprofen 600-800 mg thrice daily with placebo to match celecoxib 100-200 mg twice daily and placebo to match naproxen 375-500 mg twice daily | Naproxen 375-500 mg twice daily with placebo to match celecoxib 100-200 mg twice daily and placebo to match ibuprofen 600-800 mg thrice daily. |
Period Title: Overall Study | |||
STARTED | 8072 | 8040 | 7969 |
COMPLETED | 5664 | 5580 | 5621 |
NOT COMPLETED | 2408 | 2460 | 2348 |
Baseline Characteristics
Arm/Group Title | Celecoxib | Ibuprofen | Naproxen | Total |
---|---|---|---|---|
Arm/Group Description | Celecoxib 100-200 mg twice daily with placebo to match ibuprofen 600-800 mg thrice daily and placebo to match naproxen 375-500 mg twice daily | Ibuprofen 600-800 mg thrice daily with placebo to match celecoxib 100-200 mg twice daily and placebo to match naproxen 375-500 mg twice daily | Naproxen 375-500 mg twice daily with placebo to match celecoxib 100-200 mg twice daily and placebo to match ibuprofen 600-800 mg thrice daily. | Total of all reporting groups |
Overall Participants | 8072 | 8040 | 7969 | 24081 |
Age (Years) [Mean (Standard Deviation) ] | ||||
Mean (Standard Deviation) [Years] |
63.0
(9.5)
|
63.2
(9.4)
|
63.3
(9.4)
|
63.2
(9.4)
|
Sex: Female, Male (Count of Participants) | ||||
Female |
5175
64.1%
|
5174
64.4%
|
5096
63.9%
|
15445
64.1%
|
Male |
2897
35.9%
|
2866
35.6%
|
2873
36.1%
|
8636
35.9%
|
Outcome Measures
Title | The First Occurrence of Antiplatelet Trialists Collaboration (APTC) Composite Endpoint, Confirmed by the Clinical Events Committee (CEC). |
---|---|
Description | APTC events are defined as a composite of any of the following events: Death due to CV causes (including cardiac, cerebrovascular, venous thromboembolic, haemorrhagic, other vascular, or unknown cause); Non-fatal MI; Non-fatal stroke (including intracranial hemorrhages, stroke of ischemic or unknown etiology). |
Time Frame | Intent to Treat (ITT) Population - 30 months; Modified ITT (MITT) Population - 42 months |
Outcome Measure Data
Analysis Population Description |
---|
ITT - The ITT population will consist of all subjects randomized for participation in the study. MITT - The MITT analysis population consisted of all randomized subjects who had received at least one dose of study drug, and contributed at least one post-baseline visit. |
Arm/Group Title | Celecoxib | Ibuprofen | Naproxen |
---|---|---|---|
Arm/Group Description | Celecoxib 100-200 mg twice daily with placebo to match ibuprofen 600-800 mg thrice daily and placebo to match naproxen 375-500 mg twice daily | Ibuprofen 600-800 mg thrice daily with placebo to match celecoxib 100-200 mg twice daily and placebo to match naproxen 375-500 mg twice daily | Naproxen 375-500 mg twice daily with placebo to match celecoxib 100-200 mg twice daily and placebo to match ibuprofen 600-800 mg thrice daily. |
Measure Participants | 8072 | 8040 | 7969 |
ITT (N = 8072, 8040, 7969) |
2.3
|
2.7
|
2.5
|
MITT (N = 8030, 7990, 7933) |
1.7
|
1.9
|
1.8
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | ITT Population | |
Type of Statistical Test | Non-Inferiority or Equivalence (legacy) | |
Comments | Non inferiority required a hazard ratio of 1.12 or lower, as well as an upper 95% confidence limit of 1.33 or lower in the ITT population and of 1.40 or lower in the MITT population. | |
Statistical Test of Hypothesis | p-Value | 0.0002 |
Comments | Non inferiority P value, α=0.025 | |
Method | Regression, Cox | |
Comments | ||
Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
Estimated Value | 0.93 | |
Confidence Interval |
(2-Sided) 95% 0.76 to 1.13 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments |
Statistical Analysis 2
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | MITT Population | |
Type of Statistical Test | Non-Inferiority or Equivalence (legacy) | |
Comments | Non-inferiority requires the hazard ratio does not exceed 1.12, and the upper bound of the two-sided 95% CI for the hazard ratio estimate does not exceed 1.40 | |
Statistical Test of Hypothesis | p-Value | 0.0001 |
Comments | Non inferiority P value, α=0.025 | |
Method | Regression, Cox | |
Comments | ||
Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
Estimated Value | 0.90 | |
Confidence Interval |
(2-Sided) 95% 0.72 to 1.14 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments |
Statistical Analysis 3
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | ITT Population | |
Type of Statistical Test | Non-Inferiority or Equivalence (legacy) | |
Comments | Non-inferiority requires the hazard ratio does not exceed 1.12, and the upper bound of the two-sided 95% CI for the hazard ratio estimate does not exceed 1.33 | |
Statistical Test of Hypothesis | p-Value | <0.0001 |
Comments | Non inferiority P value, α=0.025 | |
Method | Regression, Cox | |
Comments | ||
Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
Estimated Value | 0.86 | |
Confidence Interval |
(2-Sided) 95% 0.70 to 1.04 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments |
Statistical Analysis 4
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | MITT Population | |
Type of Statistical Test | Non-Inferiority or Equivalence (legacy) | |
Comments | Non-inferiority requires the hazard ratio does not exceed 1.12, and the upper bound of the two-sided 95% CI for the hazard ratio (HR) estimate does not exceed 1.40 | |
Statistical Test of Hypothesis | p-Value | <0.0001 |
Comments | Non-inferiority P-value, α=0.025 | |
Method | Regression, Cox | |
Comments | ||
Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
Estimated Value | 0.81 | |
Confidence Interval |
(2-Sided) 95% 0.64 to 1.02 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments |
Statistical Analysis 5
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | ITT Population | |
Type of Statistical Test | Non-Inferiority or Equivalence (legacy) | |
Comments | Non-inferiority requires the hazard ratio does not exceed 1.12, and the upper bound of the two-sided 95% CI for the hazard ratio (HR) estimate does not exceed 1.33 | |
Statistical Test of Hypothesis | p-Value | 0.0182 |
Comments | Non-inferiority P-value, α=0.025 | |
Method | Regression, Cox | |
Comments | ||
Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
Estimated Value | 1.08 | |
Confidence Interval |
(2-Sided) 95% 0.89 to 1.31 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments |
Statistical Analysis 6
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | MITT Population | |
Type of Statistical Test | Non-Inferiority or Equivalence (legacy) | |
Comments | Non-inferiority requires the hazard ratio does not exceed 1.12, and the upper bound of the two-sided 95% CI for the hazard ratio (HR) estimate does not exceed 1.40 | |
Statistical Test of Hypothesis | p-Value | 0.0250 |
Comments | Non-inferiority P-value, α=0.025 | |
Method | Regression, Cox | |
Comments | ||
Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
Estimated Value | 1.12 | |
Confidence Interval |
(2-Sided) 95% 0.89 to 1.40 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments |
Title | The First Occurrence of a Major Adverse Cardiovascular Events (MACE) |
---|---|
Description | MACE defined as the composite of CV death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA |
Time Frame | ITT Population - 30 months; MITT Population - 42 months |
Outcome Measure Data
Analysis Population Description |
---|
ITT - The ITT population will consist of all subjects randomized for participation in the study. MITT - The MITT analysis population consisted of all randomized subjects who had received at least one dose of study drug, and contributed at least one post-baseline visit. |
Arm/Group Title | Celecoxib | Ibuprofen | Naproxen |
---|---|---|---|
Arm/Group Description | Celecoxib 100-200 mg twice daily with placebo to match ibuprofen 600-800 mg thrice daily and placebo to match naproxen 375-500 mg twice daily | Ibuprofen 600-800 mg thrice daily with placebo to match celecoxib 100-200 mg twice daily and placebo to match naproxen 375-500 mg twice daily | Naproxen 375-500 mg twice daily with placebo to match celecoxib 100-200 mg twice daily and placebo to match ibuprofen 600-800 mg thrice daily. |
Measure Participants | 8072 | 8040 | 7969 |
ITT (N = 8072, 8040, 7969) |
4.2
0.1%
|
4.8
0.1%
|
4.3
0.1%
|
MITT (N = 8030, 7990, 7933) |
3.1
0%
|
3.6
0%
|
3.2
0%
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | ITT Population | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.6427 |
Comments | ||
Method | Regression, Cox | |
Comments | ||
Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
Estimated Value | 0.97 | |
Confidence Interval |
(2-Sided) 95% 0.83 to 1.12 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments |
Statistical Analysis 2
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | ITT Population | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.0597 |
Comments | ||
Method | Regression, Cox | |
Comments | ||
Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
Estimated Value | 0.87 | |
Confidence Interval |
(2-Sided) 95% 0.75 to 1.01 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments |
Statistical Analysis 3
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | ITT Population | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.1481 |
Comments | ||
Method | Regression, Cox | |
Comments | ||
Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
Estimated Value | 1.11 | |
Confidence Interval |
(2-Sided) 95% 0.96 to 1.29 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments |
Statistical Analysis 4
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | MITT Population | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.5758 |
Comments | ||
Method | Regression, Cox | |
Comments | ||
Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
Estimated Value | 0.95 | |
Confidence Interval |
(2-Sided) 95% 0.80 to 1.13 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments |
Statistical Analysis 5
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | MITT Population | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.0204 |
Comments | ||
Method | Regression, Cox | |
Comments | ||
Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
Estimated Value | 0.82 | |
Confidence Interval |
(2-Sided) 95% 0.69 to 0.97 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments |
Statistical Analysis 6
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | MITT Population | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.0751 |
Comments | ||
Method | Regression, Cox | |
Comments | ||
Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
Estimated Value | 1.17 | |
Confidence Interval |
(2-Sided) 95% 0.98 to 1.38 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments |
Title | The First Occurrence of Clinically Significant Gastrointestinal Events (CSGIE) |
---|---|
Description | CSGIE include: Gastroduodenal (GD) hemorrhage, Gastric outlet obstruction, Gastroduodenal, small bowel or large bowel perforation, Large bowel hemorrhage, Small bowel hemorrhage, Acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage, Symptomatic gastric or duodenal ulcer |
Time Frame | ITT Population - 30 months; MITT Population - 42 months |
Outcome Measure Data
Analysis Population Description |
---|
ITT - The ITT population will consist of all subjects randomized for participation in the study. MITT - The MITT analysis population consisted of all randomized subjects who had received at least one dose of study drug, and contributed at least one post-baseline visit. |
Arm/Group Title | Celecoxib | Ibuprofen | Naproxen |
---|---|---|---|
Arm/Group Description | Celecoxib 100-200 mg twice daily with placebo to match ibuprofen 600-800 mg thrice daily and placebo to match naproxen 375-500 mg twice daily | Ibuprofen 600-800 mg thrice daily with placebo to match celecoxib 100-200 mg twice daily and placebo to match naproxen 375-500 mg twice daily | Naproxen 375-500 mg twice daily with placebo to match celecoxib 100-200 mg twice daily and placebo to match ibuprofen 600-800 mg thrice daily. |
Measure Participants | 8072 | 8040 | 7969 |
ITT (N = 8072, 8040, 7969) |
0.7
0%
|
0.9
0%
|
0.7
0%
|
MITT (N = 8030, 7990, 7933) |
0.3
0%
|
0.7
0%
|
0.7
0%
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | ITT Population | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.8576 |
Comments | ||
Method | Regression, Cox | |
Comments | ||
Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
Estimated Value | 0.97 | |
Confidence Interval |
(2-Sided) 95% 0.67 to 1.40 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments |
Statistical Analysis 2
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | ITT Population | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.1202 |
Comments | ||
Method | Regression, Cox | |
Comments | ||
Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
Estimated Value | 0.76 | |
Confidence Interval |
(2-Sided) 95% 0.53 to 1.08 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments |
Statistical Analysis 3
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | ITT Population | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.1734 |
Comments | ||
Method | Regression, Cox | |
Comments | ||
Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
Estimated Value | 1.27 | |
Confidence Interval |
(2-Sided) 95% 0.90 to 1.81 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments |
Statistical Analysis 4
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | MITT Population | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.0041 |
Comments | ||
Method | Regression, Cox | |
Comments | ||
Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
Estimated Value | 0.51 | |
Confidence Interval |
(2-Sided) 95% 0.32 to 0.81 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments |
Statistical Analysis 5
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | MITT Population | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.0003 |
Comments | ||
Method | Regression, Cox | |
Comments | ||
Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
Estimated Value | 0.43 | |
Confidence Interval |
(2-Sided) 95% 0.27 to 0.68 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments |
Statistical Analysis 6
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | MITT Population | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.4243 |
Comments | ||
Method | Regression, Cox | |
Comments | ||
Method of Estimation | Estimation Parameter | Hazard Ratio (HR) |
Estimated Value | 1.16 | |
Confidence Interval |
(2-Sided) 95% 0.80 to 1.69 |
|
Parameter Dispersion |
Type: Value: |
|
Estimation Comments |
Title | Change From Baseline in Patient's Assessment of Arthritis Pain (VAS) |
---|---|
Description | VAS question "How much pain do you have" was graded on a scale from 0 to 100 with 0 indicating "No pain" and 100 indicating "Worst possible pain". |
Time Frame | ITT and MITT Population - Baseline to 42 months |
Outcome Measure Data
Analysis Population Description |
---|
ITT - The ITT population will consist of all subjects randomized for participation in the study. MITT - The MITT analysis population consisted of all randomized subjects who had received at least one dose of study drug, and contributed at least one post-baseline visit. |
Arm/Group Title | Celecoxib | Ibuprofen | Naproxen |
---|---|---|---|
Arm/Group Description | Celecoxib 100-200 mg twice daily with placebo to match ibuprofen 600-800 mg thrice daily and placebo to match naproxen 375-500 mg twice daily | Ibuprofen 600-800 mg thrice daily with placebo to match celecoxib 100-200 mg twice daily and placebo to match naproxen 375-500 mg twice daily | Naproxen 375-500 mg twice daily with placebo to match celecoxib 100-200 mg twice daily and placebo to match ibuprofen 600-800 mg thrice daily. |
Measure Participants | 8072 | 8040 | 7969 |
Baseline (ITT) N= 8014, 8001, 7928 |
54.0
(23.53)
0.7%
|
54.1
(23.58)
0.7%
|
54.1
(24.04)
0.7%
|
Change-Baseline to Mon1 (ITT) N=7382, 7379, 7325 |
-8.2
(24.69)
-0.1%
|
-9.0
(25.69)
-0.1%
|
-9.9
(25.53)
-0.1%
|
Change-Baseline to Mon2 (ITT) N=7180, 7090, 7149 |
-10.5
(26.39)
-0.1%
|
-10.6
(26.92)
-0.1%
|
-11.1
(26.83)
-0.1%
|
Change-Baseline to Mon4 (ITT) N=6777, 6696, 6740 |
-11.4
(27.70)
-0.1%
|
-11.7
(28.10)
-0.1%
|
-12.3
(27.80)
-0.2%
|
Change-Baseline to Mon8 (ITT) N=6230, 6137, 6159 |
-11.7
(28.92)
-0.1%
|
-12.1
(28.97)
-0.2%
|
-12.1
(28.83)
-0.2%
|
Change-Baseline to Mon12 (ITT) N=5792, 5696, 5846 |
-11.0
(29.15)
-0.1%
|
-11.6
(29.29)
-0.1%
|
-11.9
(29.30)
-0.1%
|
Change-Baseline to Mon18 (ITT) N=5310, 5181. 5246 |
-11.3
(29.11)
-0.1%
|
-11.3
(29.10)
-0.1%
|
-11.7
(29.33)
-0.1%
|
Change-Baseline to Mon24 (ITT) N=4818, 4776, 4785 |
-11.3
(29.44)
-0.1%
|
-11.5
(28.98)
-0.1%
|
-11.4
(29.27)
-0.1%
|
Change-Baseline to Mon30 (ITT) N=4140, 4069, 4086 |
-10.5
(29.81)
-0.1%
|
-11.2
(29.71)
-0.1%
|
-11.3
(29.71)
-0.1%
|
Change-Baseline to Mon36 (ITT) N=3692, 3627, 3635 |
-10.1
(29.61)
-0.1%
|
-10.7
(29.62)
-0.1%
|
-11.6
(29.80)
-0.1%
|
Change-Baseline to Mon42 (ITT) N=3469, 3406, 3439 |
-11.4
(29.78)
-0.1%
|
-11.1
(30.14)
-0.1%
|
-12.1
(30.27)
-0.2%
|
Baseline (MITT) N=7974, 7954, 7894 |
54.0
(23.53)
0.7%
|
54.1
(23.58)
0.7%
|
54.1
(24.02)
0.7%
|
Change-Baseline to Mon1 MITT N=7372, 7367, 7321 |
-8.2
(24.69)
-0.1%
|
-9.0
(25.67)
-0.1%
|
-9.9
(25.53)
-0.1%
|
Change-Baseline to Mon2 MITT N=7170, 7078, 7142 |
-10.5
(26.38)
-0.1%
|
-10.6
(26.92)
-0.1%
|
-11.1
(26.84)
-0.1%
|
Change-Baseline to Mon4 MITT N=6772, 6686, 6732 |
-11.4
(27.70)
-0.1%
|
-11.7
(28.10)
-0.1%
|
-12.3
(27.81)
-0.2%
|
Change-Baseline to Mon8 MITT N=6224, 6128, 6155 |
-11.7
(28.93)
-0.1%
|
-12.1
(28.97)
-0.2%
|
-12.1
(28.84)
-0.2%
|
Change-Baseline to Mon12 MITT N=5787, 5689, 5844 |
-11.0
(29.16)
-0.1%
|
-11.6
(29.30)
-0.1%
|
-11.9
(29.30)
-0.1%
|
Change-Baseline to Mon18 MITT N=5305, 5175, 5242 |
-11.3
(29.11)
-0.1%
|
-11.3
(29.12)
-0.1%
|
-11.7
(29.33)
-0.1%
|
Change-Baseline to Mon24 MITT N=4815, 4769, 4782 |
-11.4
(29.44)
-0.1%
|
-11.5
(29.00)
-0.1%
|
-11.3
(29.26)
-0.1%
|
Change-Baseline to Mon30 MITT N=4139, 4067, 4085 |
-10.5
(29.81)
-0.1%
|
-11.2
(29.71)
-0.1%
|
-11.3
(29.70)
-0.1%
|
Change-Baseline to Mon36 MITT N=3691, 3623, 3635 |
-10.2
(29.61)
-0.1%
|
-10.7
(29.62)
-0.1%
|
-11.6
(29.80)
-0.1%
|
Change-Baseline to Mon42 MITT N=3468, 3404, 3438 |
-11.4
(29.78)
-0.1%
|
-11.1
(30.14)
-0.1%
|
-12.1
(30.27)
-0.2%
|
Statistical Analysis 1
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | Change from baseline to Month 1 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | <0.0001 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 1.77 | |
Confidence Interval |
(2-Sided) 95% 1.01 to 2.53 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.39 |
|
Estimation Comments |
Statistical Analysis 2
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | Change from baseline to Month 1 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.0373 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.81 | |
Confidence Interval |
(2-Sided) 95% 0.05 to 1.56 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.39 |
|
Estimation Comments |
Statistical Analysis 3
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | Change from baseline to Month 1 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.0129 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.96 | |
Confidence Interval |
(2-Sided) 95% 0.20 to 1.72 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.39 |
|
Estimation Comments |
Statistical Analysis 4
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | Change from baseline to Month 2 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.1830 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.52 | |
Confidence Interval |
(2-Sided) 95% -0.25 to 1.29 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.39 |
|
Estimation Comments |
Statistical Analysis 5
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | Change from baseline to Month 2 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.7777 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | -0.11 | |
Confidence Interval |
(2-Sided) 95% -0.88 to 0.66 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.39 |
|
Estimation Comments |
Statistical Analysis 6
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | Change from baseline to Month 2 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.1072 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.63 | |
Confidence Interval |
(2-Sided) 95% -0.14 to 1.40 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.39 |
|
Estimation Comments |
Statistical Analysis 7
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | Change from baseline to Month 4 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.8237 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.67 | |
Confidence Interval |
(2-Sided) 95% -0.12 to 1.46 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.40 |
|
Estimation Comments |
Statistical Analysis 8
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | Change from baseline to Month 4 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.8237 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | -0.09 | |
Confidence Interval |
(2-Sided) 95% -0.88 to 0.70 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.40 |
|
Estimation Comments |
Statistical Analysis 9
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | Change from baseline to Month 4 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.0587 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.76 | |
Confidence Interval |
(2-Sided) 95% -0.03 to 1.55 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.40 |
|
Estimation Comments |
Statistical Analysis 10
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | Change from baseline to Month 8 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.3129 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.42 | |
Confidence Interval |
(2-Sided) 95% -0.39 to 1.23 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.41 |
|
Estimation Comments |
Statistical Analysis 11
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | Change from baseline to Month 8 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.6526 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.19 | |
Confidence Interval |
(2-Sided) 95% -0.63 to 1.00 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.41 |
|
Estimation Comments |
Statistical Analysis 12
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | Change from baseline to Month 8 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.5774 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.23 | |
Confidence Interval |
(2-Sided) 95% -0.58 to 1.05 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.42 |
|
Estimation Comments |
Statistical Analysis 13
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | Change from baseline to Month 12 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.0632 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.79 | |
Confidence Interval |
(2-Sided) 95% -0.04 to 1.62 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.42 |
|
Estimation Comments |
Statistical Analysis 14
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | Change from baseline to Month 12 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.4540 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.32 | |
Confidence Interval |
(2-Sided) 95% -0.52 to 1.15 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.43 |
|
Estimation Comments |
Statistical Analysis 15
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | Change from baseline to Month 12 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.2705 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.47 | |
Confidence Interval |
(2-Sided) 95% -0.37 to 1.30 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.43 |
|
Estimation Comments |
Statistical Analysis 16
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | Change from baseline to Month 18 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.5225 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.28 | |
Confidence Interval |
(2-Sided) 95% -0.58 to 1.14 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.44 |
|
Estimation Comments |
Statistical Analysis 17
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | Change from baseline to Month 18 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.5996 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | -0.23 | |
Confidence Interval |
(2-Sided) 95% -1.10 to 0.63 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.44 |
|
Estimation Comments |
Statistical Analysis 18
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | Change from baseline to Month 18 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.2461 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.51 | |
Confidence Interval |
(2-Sided) 95% -0.35 to 1.38 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.44 |
|
Estimation Comments |
Statistical Analysis 19
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | Change from baseline to Month 24 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.8127 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.11 | |
Confidence Interval |
(2-Sided) 95% -0.79 to 1.00 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.46 |
|
Estimation Comments |
Statistical Analysis 20
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | Change from baseline to Month 24 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.9641 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | -0.02 | |
Confidence Interval |
(2-Sided) 95% -0.92 to 0.87 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.46 |
|
Estimation Comments |
Statistical Analysis 21
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | Change from baseline to Month 24 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.7784 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.13 | |
Confidence Interval |
(2-Sided) 95% -0.77 to 1.03 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.46 |
|
Estimation Comments |
Statistical Analysis 22
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | Change from baseline to Month 30 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.2105 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.61 | |
Confidence Interval |
(2-Sided) 95% -0.34 to 1.56 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.49 |
|
Estimation Comments |
Statistical Analysis 23
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | Change from baseline to Month 30 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.2909 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.51 | |
Confidence Interval |
(2-Sided) 95% -0.44 to 1.46 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.49 |
|
Estimation Comments |
Statistical Analysis 24
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | Change from baseline to Month 30 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.8459 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.09 | |
Confidence Interval |
(2-Sided) 95% -0.86 to 1.05 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.49 |
|
Estimation Comments |
Statistical Analysis 25
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | Change from baseline to Month 36 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.1116 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.81 | |
Confidence Interval |
(2-Sided) 95% -0.19 to 1.80 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.51 |
|
Estimation Comments |
Statistical Analysis 26
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | Change from baseline to Month 36 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.9751 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.02 | |
Confidence Interval |
(2-Sided) 95% -0.98 to 1.01 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.51 |
|
Estimation Comments |
Statistical Analysis 27
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | Change from baseline to Month 36 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.1202 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.79 | |
Confidence Interval |
(2-Sided) 95% -0.21 to 1.79 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.51 |
|
Estimation Comments |
Statistical Analysis 28
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | Change from baseline to Month 42 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.3767 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.46 | |
Confidence Interval |
(2-Sided) 95% -0.56 to 1.48 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.52 |
|
Estimation Comments |
Statistical Analysis 29
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | Change from baseline to Month 42 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.1123 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | -0.83 | |
Confidence Interval |
(2-Sided) 95% -1.85 to 0.19 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.52 |
|
Estimation Comments |
Statistical Analysis 30
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | Change from baseline to Month 42 (ITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.0137 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 1.29 | |
Confidence Interval |
(2-Sided) 95% 0.26 to 2.31 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.52 |
|
Estimation Comments |
Statistical Analysis 31
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | Change from Baseline to Month 1 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | <0.0001 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 1.77 | |
Confidence Interval |
(2-Sided) 95% 1.07 to 2.47 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.36 |
|
Estimation Comments |
Statistical Analysis 32
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | Change from Baseline to Month 1 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.0197 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.84 | |
Confidence Interval |
(2-Sided) 95% 0.13 to 1.54 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.36 |
|
Estimation Comments |
Statistical Analysis 33
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | Change from Baseline to Month 1 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.0094 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.93 | |
Confidence Interval |
(2-Sided) 95% 0.23 to 1.64 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.36 |
|
Estimation Comments |
Statistical Analysis 34
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | Change from baseline to Month 2 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.1247 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.57 | |
Confidence Interval |
(2-Sided) 95% -0.16 to 1.31 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.37 |
|
Estimation Comments |
Statistical Analysis 35
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | Change from baseline to Month 2 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.8278 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | -0.08 | |
Confidence Interval |
(2-Sided) 95% -0.81 to 0.65 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.37 |
|
Estimation Comments |
Statistical Analysis 36
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | Change from baseline to Month 2 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.0802 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.65 | |
Confidence Interval |
(2-Sided) 95% -0.08 to 1.39 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.37 |
|
Estimation Comments |
Statistical Analysis 37
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | Change from baseline to Month 4 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.0822 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.68 | |
Confidence Interval |
(2-Sided) 95% -0.09 to 1.46 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.39 |
|
Estimation Comments |
Statistical Analysis 38
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | Change from baseline to Month 4 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.8314 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | -0.08 | |
Confidence Interval |
(2-Sided) 95% -0.86 to 0.69 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.39 |
|
Estimation Comments |
Statistical Analysis 39
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | Change from baseline to Month 4 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.0516 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.77 | |
Confidence Interval |
(2-Sided) 95% -0.01 to 1.54 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.39 |
|
Estimation Comments |
Statistical Analysis 40
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | Change from baseline to Month 8 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.3202 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.42 | |
Confidence Interval |
(2-Sided) 95% -0.40 to 1.24 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.42 |
|
Estimation Comments |
Statistical Analysis 41
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | Change from baseline to Month 8 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.5893 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.23 | |
Confidence Interval |
(2-Sided) 95% -0.60 to 1.05 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.42 |
|
Estimation Comments |
Statistical Analysis 42
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | Change from baseline to Month 8 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.6510 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.19 | |
Confidence Interval |
(2-Sided) 95% -0.63 to 1.01 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.42 |
|
Estimation Comments |
Statistical Analysis 43
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | Change from baseline to Month 12 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.0796 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.76 | |
Confidence Interval |
(2-Sided) 95% -0.09 to 1.62 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.44 |
|
Estimation Comments |
Statistical Analysis 44
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | Change from baseline to Month 12 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.5061 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.29 | |
Confidence Interval |
(2-Sided) 95% -0.57 to 1.15 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.44 |
|
Estimation Comments |
Statistical Analysis 45
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | Change from baseline to Month 12 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.2796 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.47 | |
Confidence Interval |
(2-Sided) 95% -0.38 to 1.33 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.44 |
|
Estimation Comments |
Statistical Analysis 46
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | Change from baseline to Month 18 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.6725 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.19 | |
Confidence Interval |
(2-Sided) 95% -0.69 to 1.08 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.45 |
|
Estimation Comments |
Statistical Analysis 47
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | Change from baseline to Month 18 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.6381 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | -0.21 | |
Confidence Interval |
(2-Sided) 95% -1.10 to 0.67 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.45 |
|
Estimation Comments |
Statistical Analysis 48
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | Change from baseline to Month 18 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.3737 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.40 | |
Confidence Interval |
(2-Sided) 95% -0.49 to 1.29 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.45 |
|
Estimation Comments |
Statistical Analysis 49
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | Change from baseline to Month 24 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.9139 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.05 | |
Confidence Interval |
(2-Sided) 95% -0.87 to 0.97 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.47 |
|
Estimation Comments |
Statistical Analysis 50
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | Change from baseline to Month 24 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.9998 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.00 | |
Confidence Interval |
(2-Sided) 95% -0.92 to 0.92 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.47 |
|
Estimation Comments |
Statistical Analysis 51
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | Change from baseline to Month 24 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.9144 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.05 | |
Confidence Interval |
(2-Sided) 95% -0.88 to 0.98 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.47 |
|
Estimation Comments |
Statistical Analysis 52
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | Change from baseline to Month 30 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.2250 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.62 | |
Confidence Interval |
(2-Sided) 95% -0.38 to 1.61 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.51 |
|
Estimation Comments |
Statistical Analysis 53
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | Change from baseline to Month 30 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.2758 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.55 | |
Confidence Interval |
(2-Sided) 95% -0.44 to 1.55 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.51 |
|
Estimation Comments |
Statistical Analysis 54
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | Change from baseline to Month 30 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.9030 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.06 | |
Confidence Interval |
(2-Sided) 95% -0.94 to 1.06 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.51 |
|
Estimation Comments |
Statistical Analysis 55
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | Change from baseline to Month 36 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.0910 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.90 | |
Confidence Interval |
(2-Sided) 95% -0.14 to 1.94 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.53 |
|
Estimation Comments |
Statistical Analysis 56
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | Change from baseline to Month 36 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.7668 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.16 | |
Confidence Interval |
(2-Sided) 95% -0.88 to 1.20 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.53 |
|
Estimation Comments |
Statistical Analysis 57
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | Change from baseline to Month 36 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.1653 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.74 | |
Confidence Interval |
(2-Sided) 95% -0.31 to 1.78 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.53 |
|
Estimation Comments |
Statistical Analysis 58
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Naproxen |
---|---|---|
Comments | Change from baseline to Month 42 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.4323 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 0.43 | |
Confidence Interval |
(2-Sided) 95% -0.65 to 1.52 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.55 |
|
Estimation Comments |
Statistical Analysis 59
Statistical Analysis Overview | Comparison Group Selection | Celecoxib, Ibuprofen |
---|---|---|
Comments | Change from baseline to Month 42 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.1439 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | -0.81 | |
Confidence Interval |
(2-Sided) 95% -1.89 to 0.28 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.55 |
|
Estimation Comments |
Statistical Analysis 60
Statistical Analysis Overview | Comparison Group Selection | Ibuprofen, Naproxen |
---|---|---|
Comments | Change from baseline to Month 42 (MITT) | |
Type of Statistical Test | Superiority or Other (legacy) | |
Comments | ||
Statistical Test of Hypothesis | p-Value | 0.0251 |
Comments | ||
Method | Mixed Models Analysis | |
Comments | ||
Method of Estimation | Estimation Parameter | Mean Difference (Final Values) |
Estimated Value | 1.24 | |
Confidence Interval |
(2-Sided) 95% 0.16 to 2.33 |
|
Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.55 |
|
Estimation Comments |
Adverse Events
Time Frame | Adverse events were reported from the signing of the informed consent throughout the entire study period (42 months) and including 30 calendar days after the last administration of the investigational product. | |||||
---|---|---|---|---|---|---|
Adverse Event Reporting Description | ||||||
Arm/Group Title | Celecoxib | Ibuprofen | Naproxen | |||
Arm/Group Description | Celecoxib 100-200 mg twice daily with placebo to match ibuprofen 600-800 mg thrice daily and placebo to match naproxen 375-500 mg twice daily | Ibuprofen 600-800 mg thrice daily with placebo to match celecoxib 100-200 mg twice daily and placebo to match naproxen 375-500 mg twice daily | Naproxen 375-500 mg twice daily with placebo to match celecoxib 100-200 mg twice daily and placebo to match ibuprofen 600-800 mg thrice daily. | |||
All Cause Mortality |
||||||
Celecoxib | Ibuprofen | Naproxen | ||||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | / (NaN) | / (NaN) | / (NaN) | |||
Serious Adverse Events |
||||||
Celecoxib | Ibuprofen | Naproxen | ||||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 1473/8030 (18.3%) | 1624/7992 (20.3%) | 1611/7933 (20.3%) | |||
Blood and lymphatic system disorders | ||||||
Anaemia | 15/8030 (0.2%) | 34/7992 (0.4%) | 24/7933 (0.3%) | |||
Anaemia vitamin B12 deficiency | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Aplastic anaemia | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Coagulopathy | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Haemorrhagic anaemia | 2/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Hypochromic anaemia | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Iron deficiency anaemia | 2/8030 (0%) | 10/7992 (0.1%) | 11/7933 (0.1%) | |||
Leukocytosis | 1/8030 (0%) | 2/7992 (0%) | 5/7933 (0.1%) | |||
Leukopenia | 2/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Lymphadenopathy mediastinal | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Microcytic anaemia | 0/8030 (0%) | 0/7992 (0%) | 3/7933 (0%) | |||
Pancytopenia | 2/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Thrombocytopenia | 1/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Thrombocytosis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Cardiac disorders | ||||||
Acute coronary syndrome | 7/8030 (0.1%) | 7/7992 (0.1%) | 3/7933 (0%) | |||
Acute left ventricular failure | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Acute myocardial infarction | 22/8030 (0.3%) | 20/7992 (0.3%) | 18/7933 (0.2%) | |||
Angina pectoris | 13/8030 (0.2%) | 11/7992 (0.1%) | 13/7933 (0.2%) | |||
Angina unstable | 45/8030 (0.6%) | 41/7992 (0.5%) | 60/7933 (0.8%) | |||
Aortic valve disease | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Aortic valve incompetence | 0/8030 (0%) | 2/7992 (0%) | 3/7933 (0%) | |||
Aortic valve stenosis | 3/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Arrhythmia | 1/8030 (0%) | 7/7992 (0.1%) | 3/7933 (0%) | |||
Arrhythmia supraventricular | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Arteriosclerosis coronary artery | 5/8030 (0.1%) | 5/7992 (0.1%) | 7/7933 (0.1%) | |||
Arteriospasm coronary | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Atrial fibrillation | 35/8030 (0.4%) | 39/7992 (0.5%) | 36/7933 (0.5%) | |||
Atrial flutter | 6/8030 (0.1%) | 4/7992 (0.1%) | 4/7933 (0.1%) | |||
Atrioventricular block | 1/8030 (0%) | 3/7992 (0%) | 0/7933 (0%) | |||
Atrioventricular block complete | 1/8030 (0%) | 7/7992 (0.1%) | 2/7933 (0%) | |||
Atrioventricular block second degree | 2/8030 (0%) | 2/7992 (0%) | 3/7933 (0%) | |||
Atrioventricular dissociation | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Bradyarrhythmia | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Bradycardia | 10/8030 (0.1%) | 11/7992 (0.1%) | 6/7933 (0.1%) | |||
Bundle branch block left | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Bundle branch block right | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Cardiac aneurysm | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Cardiac arrest | 6/8030 (0.1%) | 9/7992 (0.1%) | 6/7933 (0.1%) | |||
Cardiac disorder | 1/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Cardiac failure | 2/8030 (0%) | 8/7992 (0.1%) | 4/7933 (0.1%) | |||
Cardiac failure chronic | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Cardiac failure congestive | 31/8030 (0.4%) | 41/7992 (0.5%) | 41/7933 (0.5%) | |||
Cardiac tamponade | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Cardiac valve disease | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Cardiac ventricular thrombosis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Cardio-respiratory arrest | 6/8030 (0.1%) | 5/7992 (0.1%) | 4/7933 (0.1%) | |||
Cardiogenic shock | 0/8030 (0%) | 3/7992 (0%) | 2/7933 (0%) | |||
Cardiomyopathy | 3/8030 (0%) | 4/7992 (0.1%) | 2/7933 (0%) | |||
Cardiopulmonary failure | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Cardiovascular disorder | 0/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Congestive cardiomyopathy | 1/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Cor pulmonale chronic | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Coronary artery disease | 42/8030 (0.5%) | 40/7992 (0.5%) | 44/7933 (0.6%) | |||
Coronary artery insufficiency | 1/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Coronary artery occlusion | 9/8030 (0.1%) | 8/7992 (0.1%) | 8/7933 (0.1%) | |||
Coronary artery stenosis | 4/8030 (0%) | 9/7992 (0.1%) | 6/7933 (0.1%) | |||
Coronary artery thrombosis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Extrasystoles | 2/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Heart valve incompetence | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Hypertensive cardiomyopathy | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Hypertensive heart disease | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Ischaemic cardiomyopathy | 3/8030 (0%) | 0/7992 (0%) | 3/7933 (0%) | |||
Left ventricular dysfunction | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Left ventricular failure | 2/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Mitral valve disease | 1/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Mitral valve incompetence | 2/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Myocardial infarction | 45/8030 (0.6%) | 70/7992 (0.9%) | 48/7933 (0.6%) | |||
Myocardial ischaemia | 2/8030 (0%) | 7/7992 (0.1%) | 3/7933 (0%) | |||
Nodal arrhythmia | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Palpitations | 2/8030 (0%) | 3/7992 (0%) | 4/7933 (0.1%) | |||
Pericardial effusion | 1/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Pericarditis | 0/8030 (0%) | 1/7992 (0%) | 4/7933 (0.1%) | |||
Pleuropericarditis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Postinfarction angina | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Prinzmetal angina | 2/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Silent myocardial infarction | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Sinus bradycardia | 0/8030 (0%) | 3/7992 (0%) | 3/7933 (0%) | |||
Sinus node dysfunction | 2/8030 (0%) | 3/7992 (0%) | 4/7933 (0.1%) | |||
Sinus tachycardia | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Supraventricular extrasystoles | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Supraventricular tachycardia | 1/8030 (0%) | 8/7992 (0.1%) | 4/7933 (0.1%) | |||
Tachyarrhythmia | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Tachycardia | 2/8030 (0%) | 2/7992 (0%) | 5/7933 (0.1%) | |||
Tricuspid valve incompetence | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Ventricular extrasystoles | 0/8030 (0%) | 3/7992 (0%) | 3/7933 (0%) | |||
Ventricular fibrillation | 0/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Ventricular tachycardia | 0/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Bradycardia and atrial flutter with hospitalization cardiorespiratory arrest and ischemia dilated | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Cardiomyopathy and non-ST elevation MI and atherosclerosis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Congenital, familial and genetic disorders | ||||||
Arteriovenous malformation | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Atrial septal defect | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Cardiac septal defect | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Cerebrovascular arteriovenous malformation | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Choledochal cyst | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Developmental hip dysplasia | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Diverticulitis Meckel's | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Haemorrhagic arteriovenous malformation | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Hypertrophic cardiomyopathy | 0/8030 (0%) | 3/7992 (0%) | 0/7933 (0%) | |||
Renal hypoplasia | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Ear and labyrinth disorders | ||||||
Deafness | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Ear discomfort | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Vertigo | 5/8030 (0.1%) | 2/7992 (0%) | 8/7933 (0.1%) | |||
Vertigo positional | 0/8030 (0%) | 3/7992 (0%) | 3/7933 (0%) | |||
Endocrine disorders | ||||||
Adrenal haemorrhage | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Adrenal insufficiency | 2/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Autoimmune thyroiditis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Goitre | 2/8030 (0%) | 4/7992 (0.1%) | 0/7933 (0%) | |||
Hyperparathyroidism | 3/8030 (0%) | 4/7992 (0.1%) | 0/7933 (0%) | |||
Hyperparathyroidism primary | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Hyperthyroidism | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Hypogonadism | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Hypoparathyroidism | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Inappropriate antidiuretic hormone secretion | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Myxoedema | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Parathyroid disorder | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Thyroid mass | 2/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Eye disorders | ||||||
Cataract | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Diplopia | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Eye haemorrhage | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Glaucoma | 0/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Optic neuropathy | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Retinal detachment | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Retinal haemorrhage | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Retinal vein occlusion | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Vision blurred | 1/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Visual impairment | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Vitreous detachment | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Gastrointestinal disorders | ||||||
Abdominal adhesions | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Abdominal discomfort | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Abdominal hernia | 5/8030 (0.1%) | 4/7992 (0.1%) | 7/7933 (0.1%) | |||
Abdominal incarcerated hernia | 3/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Abdominal pain | 14/8030 (0.2%) | 7/7992 (0.1%) | 13/7933 (0.2%) | |||
Abdominal pain lower | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Abdominal pain upper | 2/8030 (0%) | 3/7992 (0%) | 2/7933 (0%) | |||
Abdominal wall haematoma | 0/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Ascites | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Autoimmune pancreatitis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Chronic gastritis | 0/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Colitis | 6/8030 (0.1%) | 3/7992 (0%) | 3/7933 (0%) | |||
Colitis ischaemic | 1/8030 (0%) | 4/7992 (0.1%) | 4/7933 (0.1%) | |||
Colitis ulcerative | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Colonic fistula | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Colonic pseudo-obstruction | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Constipation | 1/8030 (0%) | 3/7992 (0%) | 1/7933 (0%) | |||
Crohn's disease | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Diarrhoea | 3/8030 (0%) | 8/7992 (0.1%) | 5/7933 (0.1%) | |||
Diarrhoea haemorrhagic | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Diverticular perforation | 0/8030 (0%) | 3/7992 (0%) | 1/7933 (0%) | |||
Diverticulum | 6/8030 (0.1%) | 0/7992 (0%) | 2/7933 (0%) | |||
Diverticulum intestinal | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Diverticulum intestinal haemorrhagic | 1/8030 (0%) | 2/7992 (0%) | 2/7933 (0%) | |||
Duodenal ulcer | 2/8030 (0%) | 2/7992 (0%) | 3/7933 (0%) | |||
Duodenal ulcer haemorrhage | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Duodenal ulcer perforation | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Duodenitis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Dysphagia | 1/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Enteritis | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Enterocele | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Enterovesical fistula | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Erosive duodenitis | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Erosive oesophagitis | 1/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Faecaloma | 0/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Femoral hernia | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Food poisoning | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Gastric perforation | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Gastric ulcer | 1/8030 (0%) | 12/7992 (0.2%) | 5/7933 (0.1%) | |||
Gastric ulcer haemorrhage | 2/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Gastric varices | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Gastric varices haemorrhage | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Gastric volvulus | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Gastritis | 3/8030 (0%) | 6/7992 (0.1%) | 5/7933 (0.1%) | |||
Gastritis erosive | 1/8030 (0%) | 6/7992 (0.1%) | 1/7933 (0%) | |||
Gastritis haemorrhagic | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Gastroduodenal haemorrhage | 0/8030 (0%) | 3/7992 (0%) | 2/7933 (0%) | |||
Gastroduodenitis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Gastrointestinal haemorrhage | 7/8030 (0.1%) | 8/7992 (0.1%) | 8/7933 (0.1%) | |||
Gastrointestinal hypomotility | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Gastrointestinal necrosis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Gastrointestinal stenosis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Gastrointestinal ulcer | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Gastrooesophageal reflux disease | 1/8030 (0%) | 3/7992 (0%) | 4/7933 (0.1%) | |||
Haematochezia | 0/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Haemorrhoidal haemorrhage | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Haemorrhoids | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Hernial eventration | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Hiatus hernia | 2/8030 (0%) | 2/7992 (0%) | 2/7933 (0%) | |||
Ileal ulcer | 2/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Ileus | 1/8030 (0%) | 3/7992 (0%) | 1/7933 (0%) | |||
Ileus paralytic | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Incarcerated inguinal hernia | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Incarcerated umbilical hernia | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Inflammatory bowel disease | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Inguinal hernia | 5/8030 (0.1%) | 2/7992 (0%) | 0/7933 (0%) | |||
Intestinal dilatation | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Intestinal ischaemia | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Intestinal obstruction | 2/8030 (0%) | 2/7992 (0%) | 5/7933 (0.1%) | |||
Intestinal perforation | 0/8030 (0%) | 0/7992 (0%) | 3/7933 (0%) | |||
Intestinal ulcer | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Intra-abdominal haemorrhage | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Irritable bowel syndrome | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Large intestinal haemorrhage | 4/8030 (0%) | 3/7992 (0%) | 0/7933 (0%) | |||
Large intestinal obstruction | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Large intestinal ulcer | 1/8030 (0%) | 2/7992 (0%) | 2/7933 (0%) | |||
Large intestine perforation | 0/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Large intestine polyp | 1/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Localised intraabdominal fluid collection | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Lower gastrointestinal haemorrhage | 2/8030 (0%) | 3/7992 (0%) | 3/7933 (0%) | |||
Megacolon | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Melaena | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Mesenteric artery stenosis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Nausea | 5/8030 (0.1%) | 3/7992 (0%) | 6/7933 (0.1%) | |||
Necrotising colitis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Neutropenic colitis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Obstruction gastric | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Oedematous pancreatitis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Oesophageal spasm | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Oesophageal stenosis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Oesophageal ulcer | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Oesophagitis | 1/8030 (0%) | 2/7992 (0%) | 2/7933 (0%) | |||
Oesophagitis ulcerative | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Pancreatic cyst | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Pancreatic necrosis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Pancreatitis | 8/8030 (0.1%) | 12/7992 (0.2%) | 12/7933 (0.2%) | |||
Pancreatitis acute | 3/8030 (0%) | 4/7992 (0.1%) | 6/7933 (0.1%) | |||
Pancreatitis chronic | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Pancreatitis necrotising | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Peptic ulcer haemorrhage | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Rectal haemorrhage | 4/8030 (0%) | 4/7992 (0.1%) | 2/7933 (0%) | |||
Retroperitoneal haematoma | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Retroperitoneal mass | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Salivary gland calculus | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Small intestinal obstruction | 7/8030 (0.1%) | 9/7992 (0.1%) | 8/7933 (0.1%) | |||
Umbilical hernia | 4/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Upper gastrointestinal haemorrhage | 1/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Volvulus | 0/8030 (0%) | 3/7992 (0%) | 0/7933 (0%) | |||
Vomiting | 5/8030 (0.1%) | 7/7992 (0.1%) | 7/7933 (0.1%) | |||
General disorders | ||||||
Adverse drug reaction | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Asthenia | 4/8030 (0%) | 5/7992 (0.1%) | 4/7933 (0.1%) | |||
Cardiac death | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Chest discomfort | 2/8030 (0%) | 5/7992 (0.1%) | 4/7933 (0.1%) | |||
Chest pain | 52/8030 (0.6%) | 84/7992 (1.1%) | 73/7933 (0.9%) | |||
Complication associated with device | 1/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Cyst rupture | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Death | 4/8030 (0%) | 3/7992 (0%) | 7/7933 (0.1%) | |||
Device related thrombosis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Drowning | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Drug interaction | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Electrocution | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Fatigue | 2/8030 (0%) | 2/7992 (0%) | 2/7933 (0%) | |||
Feeling hot | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
General physical health deterioration | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Generalised oedema | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Granuloma | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Hernia | 0/8030 (0%) | 3/7992 (0%) | 1/7933 (0%) | |||
Ill-defined disorder | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Impaired healing | 1/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Incarcerated hernia | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Influenza like illness | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Local swelling | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Malaise | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Multiple organ dysfunction syndrome | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Necrosis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Non-cardiac chest pain | 23/8030 (0.3%) | 19/7992 (0.2%) | 23/7933 (0.3%) | |||
Oedema peripheral | 4/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Organ failure | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Pain | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Pelvic mass | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Peripheral swelling | 1/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Polyp | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Pyrexia | 0/8030 (0%) | 4/7992 (0.1%) | 3/7933 (0%) | |||
Sudden cardiac death | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Sudden death | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Surgical failure | 0/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Systemic inflammatory response syndrome | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Vascular stent stenosis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Vascular stent thrombosis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Hepatobiliary disorders | ||||||
Acute hepatic failure | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Bile duct obstruction | 2/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Bile duct stone | 1/8030 (0%) | 0/7992 (0%) | 5/7933 (0.1%) | |||
Biliary colic | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Biliary dyskinesia | 1/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Biliary tract disorder | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Cholangitis | 1/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Cholecystitis | 8/8030 (0.1%) | 10/7992 (0.1%) | 11/7933 (0.1%) | |||
Cholecystitis acute | 9/8030 (0.1%) | 11/7992 (0.1%) | 5/7933 (0.1%) | |||
Cholecystitis chronic | 1/8030 (0%) | 0/7992 (0%) | 3/7933 (0%) | |||
Cholelithiasis | 24/8030 (0.3%) | 23/7992 (0.3%) | 12/7933 (0.2%) | |||
Cholestasis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Drug-induced liver injury | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Gallbladder disorder | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Hepatic cyst | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Hepatic failure | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Hepatic function abnormal | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Hepatic lesion | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Hepatic vein thrombosis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Hepatitis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Hepatitis alcoholic | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Jaundice cholestatic | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Jaundice hepatocellular | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Liver disorder | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Portal vein thrombosis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Immune system disorders | ||||||
Allergy to arthropod bite | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Anaphylactic reaction | 0/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Anaphylactic shock | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Drug hypersensitivity | 0/8030 (0%) | 0/7992 (0%) | 3/7933 (0%) | |||
Hypersensitivity | 1/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Sarcoidosis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Infections and infestations | ||||||
Abdominal abscess | 1/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Abdominal infection | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Abdominal wall abscess | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Abscess intestinal | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Abscess limb | 2/8030 (0%) | 3/7992 (0%) | 2/7933 (0%) | |||
Abscess neck | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Acute sinusitis | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Anal abscess | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Appendiceal abscess | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Appendicitis | 7/8030 (0.1%) | 7/7992 (0.1%) | 7/7933 (0.1%) | |||
Appendicitis perforated | 2/8030 (0%) | 3/7992 (0%) | 2/7933 (0%) | |||
Arthritis bacterial | 5/8030 (0.1%) | 2/7992 (0%) | 2/7933 (0%) | |||
Arthritis infective | 0/8030 (0%) | 2/7992 (0%) | 3/7933 (0%) | |||
Atypical pneumonia | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Bacteraemia | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Bacterial diarrhoea | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Bacterial disease carrier | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Bacterial infection | 1/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Bacterial sepsis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Beta haemolytic streptococcal infection | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Bone tuberculosis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Breast abscess | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Bronchitis | 10/8030 (0.1%) | 16/7992 (0.2%) | 17/7933 (0.2%) | |||
Bronchitis bacterial | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Bursitis infective | 2/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Campylobacter gastroenteritis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Cellulitis | 29/8030 (0.4%) | 32/7992 (0.4%) | 32/7933 (0.4%) | |||
Cellulitis of male external genital organ | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Cellulitis staphylococcal | 1/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Cholecystitis infective | 0/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Chronic pulmonary histoplasmosis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Chronic sinusitis | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Clostridium difficile colitis | 2/8030 (0%) | 4/7992 (0.1%) | 4/7933 (0.1%) | |||
Clostridium difficile infection | 1/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Cystitis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Cytomegalovirus infection | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Dengue fever | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Device related infection | 1/8030 (0%) | 4/7992 (0.1%) | 3/7933 (0%) | |||
Diabetic foot infection | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Diverticulitis | 12/8030 (0.1%) | 13/7992 (0.2%) | 17/7933 (0.2%) | |||
Embolic pneumonia | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Empyema | 1/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Encephalitis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Endocarditis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Epididymitis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Erysipelas | 1/8030 (0%) | 2/7992 (0%) | 2/7933 (0%) | |||
Escherichia bacteraemia | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Escherichia infection | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Escherichia sepsis | 1/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Escherichia urinary tract infection | 2/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Extradural abscess | 2/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Gangrene | 1/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Gastroenteritis | 12/8030 (0.1%) | 21/7992 (0.3%) | 7/7933 (0.1%) | |||
Gastroenteritis bacterial | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Gastroenteritis viral | 4/8030 (0%) | 4/7992 (0.1%) | 3/7933 (0%) | |||
Gastrointestinal infection | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Gastrointestinal viral infection | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Genitourinary tract infection | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Groin abscess | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
H1N1 influenza | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
HIV infection | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Haemophilus infection | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Helicobacter gastritis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Hepatic infection | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Herpes oesophagitis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Herpes simplex | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Herpes zoster | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Incision site infection | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Infected skin ulcer | 1/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Infection | 1/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Infectious colitis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Infectious pleural effusion | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Infective exacerbation of chronic obstructive airways disease | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Infective tenosynovitis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Influenza | 2/8030 (0%) | 4/7992 (0.1%) | 1/7933 (0%) | |||
Intervertebral discitis | 1/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Joint abscess | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Kidney infection | 1/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Klebsiella bacteraemia | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Klebsiella infection | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Liver abscess | 2/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Localised infection | 4/8030 (0%) | 2/7992 (0%) | 5/7933 (0.1%) | |||
Lower respiratory tract infection | 0/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Lung infection | 1/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Lymphangitis | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Meningitis bacterial | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Meningitis pneumococcal | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Necrotising fasciitis | 0/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Nosocomial infection | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Ophthalmic herpes zoster | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Oral candidiasis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Orchitis | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Osteomyelitis | 9/8030 (0.1%) | 6/7992 (0.1%) | 8/7933 (0.1%) | |||
Osteomyelitis acute | 1/8030 (0%) | 0/7992 (0%) | 3/7933 (0%) | |||
Osteomyelitis chronic | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Otitis media | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Pancreatic abscess | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Pancreatitis bacterial | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Pancreatitis viral | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Parametritis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Paraspinal abscess | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Parotitis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Periodontitis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Perirectal abscess | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Peritonitis | 1/8030 (0%) | 3/7992 (0%) | 1/7933 (0%) | |||
Peritonitis bacterial | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Peritonsillar abscess | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Pharyngitis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Pharyngitis streptococcal | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Pleurisy viral | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Pneumococcal sepsis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Pneumonia | 64/8030 (0.8%) | 79/7992 (1%) | 69/7933 (0.9%) | |||
Pneumonia bacterial | 3/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Pneumonia fungal | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Pneumonia haemophilus | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Pneumonia klebsiella | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Pneumonia pseudomonal | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Pneumonia staphylococcal | 2/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Pneumonia streptococcal | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Post procedural infection | 2/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Postoperative abscess | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Postoperative wound infection | 3/8030 (0%) | 2/7992 (0%) | 2/7933 (0%) | |||
Prostate infection | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Proteus infection | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Pulmonary tuberculosis | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Pyelonephritis | 5/8030 (0.1%) | 9/7992 (0.1%) | 8/7933 (0.1%) | |||
Pyelonephritis acute | 5/8030 (0.1%) | 3/7992 (0%) | 3/7933 (0%) | |||
Pyelonephritis chronic | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Pyometra | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Respiratory tract infection | 0/8030 (0%) | 0/7992 (0%) | 3/7933 (0%) | |||
Sepsis | 19/8030 (0.2%) | 20/7992 (0.3%) | 12/7933 (0.2%) | |||
Septic arthritis staphylococcal | 1/8030 (0%) | 0/7992 (0%) | 3/7933 (0%) | |||
Septic shock | 2/8030 (0%) | 5/7992 (0.1%) | 4/7933 (0.1%) | |||
Sinusitis | 0/8030 (0%) | 5/7992 (0.1%) | 0/7933 (0%) | |||
Skin infection | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Spinal cord abscess | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Staphylococcal abscess | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Staphylococcal bacteraemia | 2/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Staphylococcal infection | 4/8030 (0%) | 2/7992 (0%) | 4/7933 (0.1%) | |||
Staphylococcal sepsis | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Staphylococcal skin infection | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Stenotrophomonas infection | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Subcutaneous abscess | 4/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Tinea pedis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Tonsillitis | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Tooth abscess | 0/8030 (0%) | 2/7992 (0%) | 2/7933 (0%) | |||
Tooth infection | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Tuberculosis | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Upper respiratory tract infection | 3/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Urinary tract infection | 16/8030 (0.2%) | 22/7992 (0.3%) | 20/7933 (0.3%) | |||
Urinary tract infection bacterial | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Urosepsis | 9/8030 (0.1%) | 8/7992 (0.1%) | 6/7933 (0.1%) | |||
Viral diarrhoea | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Viral infection | 1/8030 (0%) | 2/7992 (0%) | 3/7933 (0%) | |||
Viral upper respiratory tract infection | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Vulval abscess | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Wound infection | 1/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Wound infection staphylococcal | 0/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
MRSA | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Pyelonephritis with sepsis NFI | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Injury, poisoning and procedural complications | ||||||
Accidental exposure to product | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Acetabulum fracture | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Alcohol poisoning | 2/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Anaemia postoperative | 1/8030 (0%) | 2/7992 (0%) | 2/7933 (0%) | |||
Anastomotic leak | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Animal bite | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Ankle fracture | 10/8030 (0.1%) | 5/7992 (0.1%) | 9/7933 (0.1%) | |||
Arterial injury | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Arthropod bite | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Back injury | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Brain contusion | 2/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Burns second degree | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Burns third degree | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Cartilage injury | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Cervical vertebral fracture | 4/8030 (0%) | 0/7992 (0%) | 5/7933 (0.1%) | |||
Chest injury | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Clavicle fracture | 0/8030 (0%) | 1/7992 (0%) | 3/7933 (0%) | |||
Compression fracture | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Concussion | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Contusion | 0/8030 (0%) | 2/7992 (0%) | 2/7933 (0%) | |||
Craniocerebral injury | 1/8030 (0%) | 2/7992 (0%) | 4/7933 (0.1%) | |||
Delayed spinal fusion | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Extradural haematoma | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Eye contusion | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Face injury | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Facial bones fracture | 4/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Fall | 8/8030 (0.1%) | 11/7992 (0.1%) | 10/7933 (0.1%) | |||
Fat embolism | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Femoral neck fracture | 4/8030 (0%) | 3/7992 (0%) | 3/7933 (0%) | |||
Femur fracture | 11/8030 (0.1%) | 7/7992 (0.1%) | 18/7933 (0.2%) | |||
Fibula fracture | 3/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Foetal exposure during pregnancy | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Foot fracture | 1/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Forearm fracture | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Foreign body | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Gastrointestinal stoma complication | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Gun shot wound | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Hand fracture | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Head injury | 1/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Heat exhaustion | 2/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Hepatic rupture | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Hip fracture | 8/8030 (0.1%) | 11/7992 (0.1%) | 16/7933 (0.2%) | |||
Humerus fracture | 4/8030 (0%) | 5/7992 (0.1%) | 5/7933 (0.1%) | |||
Incisional hernia | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Injury | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Intentional overdose | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Intervertebral disc injury | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Jaw fracture | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Joint dislocation | 6/8030 (0.1%) | 5/7992 (0.1%) | 3/7933 (0%) | |||
Joint injury | 1/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Laceration | 3/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Ligament injury | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Ligament rupture | 1/8030 (0%) | 4/7992 (0.1%) | 0/7933 (0%) | |||
Limb crushing injury | 0/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Lower limb fracture | 3/8030 (0%) | 2/7992 (0%) | 3/7933 (0%) | |||
Meniscus injury | 1/8030 (0%) | 4/7992 (0.1%) | 3/7933 (0%) | |||
Multiple fractures | 2/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Multiple injuries | 0/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Muscle rupture | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Nerve injury | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Overdose | 0/8030 (0%) | 3/7992 (0%) | 3/7933 (0%) | |||
Patella fracture | 0/8030 (0%) | 4/7992 (0.1%) | 1/7933 (0%) | |||
Pelvic fracture | 2/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Periprosthetic fracture | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Perirenal haematoma | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Post concussion syndrome | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Post procedural complication | 2/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Post procedural constipation | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Post procedural haemorrhage | 3/8030 (0%) | 3/7992 (0%) | 3/7933 (0%) | |||
Post procedural oedema | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Post procedural swelling | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Post-traumatic neck syndrome | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Postoperative ileus | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Postoperative thoracic procedure complication | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Procedural complication | 2/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Procedural pain | 0/8030 (0%) | 3/7992 (0%) | 0/7933 (0%) | |||
Procedural pneumothorax | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Pubis fracture | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Pulmonary contusion | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Radius fracture | 9/8030 (0.1%) | 1/7992 (0%) | 0/7933 (0%) | |||
Respiratory fume inhalation disorder | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Rib fracture | 4/8030 (0%) | 5/7992 (0.1%) | 8/7933 (0.1%) | |||
Road traffic accident | 4/8030 (0%) | 9/7992 (0.1%) | 6/7933 (0.1%) | |||
Scapula fracture | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Seroma | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Skeletal injury | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Skin abrasion | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Skull fracture | 2/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Spinal column injury | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Spinal compression fracture | 2/8030 (0%) | 0/7992 (0%) | 10/7933 (0.1%) | |||
Spinal fracture | 0/8030 (0%) | 0/7992 (0%) | 4/7933 (0.1%) | |||
Spinal shock | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Splenic rupture | 1/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Subdural haematoma | 1/8030 (0%) | 6/7992 (0.1%) | 1/7933 (0%) | |||
Subdural haemorrhage | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Tendon rupture | 4/8030 (0%) | 6/7992 (0.1%) | 2/7933 (0%) | |||
Thermal burn | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Thoracic vertebral fracture | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Tibia fracture | 1/8030 (0%) | 0/7992 (0%) | 6/7933 (0.1%) | |||
Toxicity to various agents | 1/8030 (0%) | 2/7992 (0%) | 4/7933 (0.1%) | |||
Traumatic arthritis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Traumatic haemothorax | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Traumatic renal injury | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Ulna fracture | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Upper limb fracture | 2/8030 (0%) | 2/7992 (0%) | 4/7933 (0.1%) | |||
Urinary retention postoperative | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Urostomy complication | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Vascular graft occlusion | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Vascular graft thrombosis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Vascular pseudoaneurysm | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Wound | 0/8030 (0%) | 0/7992 (0%) | 3/7933 (0%) | |||
Wound decomposition | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Wound dehiscence | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Wound necrosis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Wound secretion | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Wrist fracture | 4/8030 (0%) | 2/7992 (0%) | 3/7933 (0%) | |||
Investigations | ||||||
Alanine aminotransferase increased | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Aspartate aminotransferase increased | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Aspiration bronchial | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Biopsy anus | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Biopsy breast | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Blood bilirubin increased | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Blood chromium increased | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Blood creatine abnormal | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Blood creatinine increased | 0/8030 (0%) | 1/7992 (0%) | 3/7933 (0%) | |||
Blood glucose abnormal | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Blood glucose increased | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Blood iron decreased | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Blood pressure increased | 1/8030 (0%) | 2/7992 (0%) | 3/7933 (0%) | |||
Blood pressure systolic increased | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Blood triglycerides increased | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Clostridium test positive | 0/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Ejection fraction | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Ejection fraction decreased | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Electrocardiogram abnormal | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Endoscopy gastrointestinal | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Fibrin D dimer increased | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Haemoglobin decreased | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Heart rate irregular | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Hepatic enzyme increased | 2/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Liver function test increased | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Occult blood positive | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Oxygen saturation decreased | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Platelet count decreased | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Platelet function test abnormal | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Staphylococcus test positive | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Transaminases increased | 2/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Troponin increased | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Weight decreased | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Metabolism and nutrition disorders | ||||||
Decreased appetite | 0/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Dehydration | 10/8030 (0.1%) | 20/7992 (0.3%) | 13/7933 (0.2%) | |||
Diabetes mellitus | 5/8030 (0.1%) | 2/7992 (0%) | 6/7933 (0.1%) | |||
Diabetes mellitus inadequate control | 2/8030 (0%) | 1/7992 (0%) | 4/7933 (0.1%) | |||
Diabetic ketoacidosis | 2/8030 (0%) | 4/7992 (0.1%) | 4/7933 (0.1%) | |||
Electrolyte imbalance | 0/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Gout | 0/8030 (0%) | 1/7992 (0%) | 3/7933 (0%) | |||
Hypercalcaemia | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Hyperglycaemia | 3/8030 (0%) | 3/7992 (0%) | 7/7933 (0.1%) | |||
Hyperkalaemia | 1/8030 (0%) | 4/7992 (0.1%) | 2/7933 (0%) | |||
Hypernatraemia | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Hyperosmolar hyperglycaemic state | 2/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Hypocalcaemia | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Hypoglycaemia | 6/8030 (0.1%) | 7/7992 (0.1%) | 8/7933 (0.1%) | |||
Hypokalaemia | 7/8030 (0.1%) | 9/7992 (0.1%) | 5/7933 (0.1%) | |||
Hypomagnesaemia | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Hyponatraemia | 7/8030 (0.1%) | 8/7992 (0.1%) | 5/7933 (0.1%) | |||
Hypophosphataemia | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Hypovolaemia | 0/8030 (0%) | 3/7992 (0%) | 1/7933 (0%) | |||
Iron deficiency | 0/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Ketoacidosis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Lactic acidosis | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Malnutrition | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Metabolic acidosis | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Obesity | 5/8030 (0.1%) | 5/7992 (0.1%) | 5/7933 (0.1%) | |||
Type 2 diabetes mellitus | 1/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Musculoskeletal and connective tissue disorders | ||||||
Arthralgia | 44/8030 (0.5%) | 33/7992 (0.4%) | 39/7933 (0.5%) | |||
Arthrofibrosis | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Arthropathy | 1/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Back pain | 14/8030 (0.2%) | 17/7992 (0.2%) | 20/7933 (0.3%) | |||
Bone cyst | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Bone disorder | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Bone erosion | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Bursitis | 2/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Cervical spinal stenosis | 8/8030 (0.1%) | 7/7992 (0.1%) | 2/7933 (0%) | |||
Chondropathy | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Compartment syndrome | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Costochondritis | 3/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Exostosis | 0/8030 (0%) | 3/7992 (0%) | 0/7933 (0%) | |||
Facet joint syndrome | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Felty's syndrome | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Fistula | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Flank pain | 0/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Foot deformity | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Fracture malunion | 0/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Gouty arthritis | 1/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Intervertebral disc degeneration | 7/8030 (0.1%) | 13/7992 (0.2%) | 11/7933 (0.1%) | |||
Intervertebral disc disorder | 3/8030 (0%) | 0/7992 (0%) | 5/7933 (0.1%) | |||
Intervertebral disc displacement | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Intervertebral disc protrusion | 19/8030 (0.2%) | 16/7992 (0.2%) | 16/7933 (0.2%) | |||
Joint ankylosis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Joint effusion | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Joint instability | 1/8030 (0%) | 2/7992 (0%) | 2/7933 (0%) | |||
Joint swelling | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Knee deformity | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Kyphosis | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Lumbar spinal stenosis | 13/8030 (0.2%) | 15/7992 (0.2%) | 20/7933 (0.3%) | |||
Meniscal degeneration | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Arthritis | 31/8030 (0.4%) | 33/7992 (0.4%) | 32/7933 (0.4%) | |||
Mobility decreased | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Muscle spasms | 1/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Muscular weakness | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Musculoskeletal chest pain | 2/8030 (0%) | 4/7992 (0.1%) | 7/7933 (0.1%) | |||
Musculoskeletal pain | 4/8030 (0%) | 5/7992 (0.1%) | 6/7933 (0.1%) | |||
Myalgia | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Neck pain | 5/8030 (0.1%) | 3/7992 (0%) | 0/7933 (0%) | |||
Osteoarthritis | 201/8030 (2.5%) | 206/7992 (2.6%) | 189/7933 (2.4%) | |||
Osteoarthropathy | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Osteolysis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Osteonecrosis | 2/8030 (0%) | 1/7992 (0%) | 3/7933 (0%) | |||
Osteoporosis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Pain in extremity | 1/8030 (0%) | 7/7992 (0.1%) | 1/7933 (0%) | |||
Pain in jaw | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Pathological fracture | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Periarthritis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Polyarthritis | 1/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Polymyositis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Pseudarthrosis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Rhabdomyolysis | 3/8030 (0%) | 4/7992 (0.1%) | 1/7933 (0%) | |||
Rheumatoid arthritis | 8/8030 (0.1%) | 5/7992 (0.1%) | 3/7933 (0%) | |||
Rotator cuff syndrome | 10/8030 (0.1%) | 7/7992 (0.1%) | 10/7933 (0.1%) | |||
Scoliosis | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Spinal column stenosis | 13/8030 (0.2%) | 12/7992 (0.2%) | 7/7933 (0.1%) | |||
Spinal osteoarthritis | 4/8030 (0%) | 16/7992 (0.2%) | 4/7933 (0.1%) | |||
Spinal pain | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Spondylitis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Spondylolisthesis | 7/8030 (0.1%) | 7/7992 (0.1%) | 10/7933 (0.1%) | |||
Synovial cyst | 0/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Tendon disorder | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Tendon pain | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Tendonitis | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Vertebral foraminal stenosis | 1/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Vertebral osteophyte | 2/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Osteoarthritis with tibial component loosening | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Neoplasms benign, malignant and unspecified (incl cysts and polyps) | ||||||
Acoustic neuroma | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Acute myeloid leukaemia | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Adenocarcinoma | 2/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Adenocarcinoma of colon | 2/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Adenocarcinoma of the cervix | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Adenocarcinoma pancreas | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Adenoma benign | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
B-cell lymphoma | 2/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Basal cell carcinoma | 3/8030 (0%) | 8/7992 (0.1%) | 4/7933 (0.1%) | |||
Benign lung neoplasm | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Benign neoplasm | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Benign ovarian tumour | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Bladder cancer | 3/8030 (0%) | 3/7992 (0%) | 2/7933 (0%) | |||
Bladder cancer recurrent | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Bladder neoplasm | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Bladder transitional cell carcinoma | 0/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Bone cancer | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Bowen's disease | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Brain neoplasm | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Brain neoplasm malignant | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Breast cancer | 20/8030 (0.2%) | 11/7992 (0.1%) | 10/7933 (0.1%) | |||
Breast cancer in situ | 1/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Breast cancer recurrent | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Breast cancer stage I | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Breast cancer stage IV | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Breast neoplasm | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Bronchioloalveolar carcinoma | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Carcinoid tumour | 0/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Carcinoid tumour of the duodenum | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Carcinoid tumour of the small bowel | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Carcinoid tumour of the stomach | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Central nervous system lymphoma | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Cervix carcinoma stage 0 | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Cholangiocarcinoma | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Chronic lymphocytic leukaemia | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Clear cell renal cell carcinoma | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Colon adenoma | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Colon cancer | 3/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Colon cancer metastatic | 0/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Colon cancer recurrent | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Colon cancer stage III | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Colon neoplasm | 2/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Diffuse large B-cell lymphoma stage II | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Endometrial adenocarcinoma | 2/8030 (0%) | 1/7992 (0%) | 4/7933 (0.1%) | |||
Endometrial cancer recurrent | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Endometrial cancer stage III | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Female reproductive neoplasm | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Follicle centre lymphoma, follicular grade I, II, III | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Follicular thyroid cancer | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Gastric cancer | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Gastric neoplasm | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Gastrointestinal melanoma | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Gastrointestinal stromal cancer | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Gastrointestinal stromal tumour | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Gastrointestinal tract adenoma | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Glioblastoma multiforme | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Hairy cell leukaemia | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Head and neck cancer | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Hepatic cancer | 0/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Hepatic cancer metastatic | 0/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Hodgkin's disease | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Intraductal proliferative breast lesion | 0/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Invasive ductal breast carcinoma | 4/8030 (0%) | 3/7992 (0%) | 5/7933 (0.1%) | |||
Large cell lung cancer stage 0 | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Laryngeal squamous cell carcinoma | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Leiomyoma | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Leukaemia | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Lip neoplasm malignant stage unspecified | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Lipoma | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Lobular breast carcinoma in situ | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Lung adenocarcinoma | 1/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Lung adenocarcinoma stage III | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Lung cancer metastatic | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Lung carcinoma cell type unspecified stage I | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Lung carcinoma cell type unspecified stage IV | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Lung neoplasm malignant | 14/8030 (0.2%) | 7/7992 (0.1%) | 12/7933 (0.2%) | |||
Lung squamous cell carcinoma stage II | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Lymphocytic leukaemia | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Lymphoma | 1/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Malignant mediastinal neoplasm | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Malignant melanoma | 4/8030 (0%) | 1/7992 (0%) | 3/7933 (0%) | |||
Malignant melanoma in situ | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Malignant neoplasm of unknown primary site | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Malignant pleural effusion | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Mantle cell lymphoma | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Meningioma | 0/8030 (0%) | 0/7992 (0%) | 3/7933 (0%) | |||
Mesothelioma | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Metastases to liver | 1/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Metastatic gastric cancer | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Metastatic malignant melanoma | 2/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Metastatic squamous cell carcinoma | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Myelodysplastic syndrome | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Neoplasm malignant | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Non-Hodgkin's lymphoma | 1/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Non-Hodgkin's lymphoma stage III | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Non-small cell lung cancer | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Oesophageal adenocarcinoma | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Oesophageal carcinoma | 1/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Oropharyngeal cancer | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Ovarian cancer | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Ovarian cancer stage III | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Pancreatic carcinoma | 2/8030 (0%) | 7/7992 (0.1%) | 3/7933 (0%) | |||
Pancreatic carcinoma metastatic | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Pancreatic carcinoma stage II | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Pancreatic carcinoma stage III | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Papillary cystadenoma lymphomatosum | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Paraproteinaemia | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Parathyroid tumour | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Parathyroid tumour benign | 0/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Pituitary tumour | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Pituitary tumour benign | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Plasma cell myeloma | 2/8030 (0%) | 1/7992 (0%) | 3/7933 (0%) | |||
Prostate cancer | 8/8030 (0.1%) | 19/7992 (0.2%) | 20/7933 (0.3%) | |||
Prostate cancer recurrent | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Rectal cancer | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Renal cancer | 1/8030 (0%) | 4/7992 (0.1%) | 2/7933 (0%) | |||
Renal cancer metastatic | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Renal cell carcinoma | 1/8030 (0%) | 3/7992 (0%) | 1/7933 (0%) | |||
Renal neoplasm | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Small cell lung cancer | 0/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Small cell lung cancer metastatic | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Squamous cell carcinoma | 3/8030 (0%) | 2/7992 (0%) | 2/7933 (0%) | |||
Squamous cell carcinoma of lung | 0/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Squamous cell carcinoma of skin | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Superficial spreading melanoma stage unspecified | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Sweat gland tumour | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Testis cancer | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Throat cancer | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Thyroid cancer | 1/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Transitional cell cancer of the renal pelvis and ureter | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Transitional cell carcinoma | 1/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Triple negative breast cancer | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Ureteric cancer | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Uterine cancer | 0/8030 (0%) | 4/7992 (0.1%) | 1/7933 (0%) | |||
Uterine leiomyoma | 0/8030 (0%) | 5/7992 (0.1%) | 3/7933 (0%) | |||
Large granular lymphocyte | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Metastatic hepatic adenocarcinoma | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Metastatic tumor possibly from squamous cell lung cancer and metastatic tumor cerebral tumor | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Nervous system disorders | ||||||
Altered state of consciousness | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Amnesia | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Aphasia | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Ataxia | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Autonomic neuropathy | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Balance disorder | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Basal ganglia infarction | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Basal ganglia stroke | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Brachial plexopathy | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Brain oedema | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Carotid arteriosclerosis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Carotid artery disease | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Carotid artery dissection | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Carotid artery occlusion | 2/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Carotid artery stenosis | 5/8030 (0.1%) | 5/7992 (0.1%) | 3/7933 (0%) | |||
Carotid artery thrombosis | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Carpal tunnel syndrome | 2/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Central nervous system lesion | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Central-alveolar hypoventilation | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Cerebellar infarction | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Cerebral cyst | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Cerebral haematoma | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Cerebral haemorrhage | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Cerebral infarction | 1/8030 (0%) | 4/7992 (0.1%) | 1/7933 (0%) | |||
Cerebral ischaemia | 1/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Cerebrospinal fluid leakage | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Cerebrovascular accident | 39/8030 (0.5%) | 34/7992 (0.4%) | 34/7933 (0.4%) | |||
Cerebrovascular disorder | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Cervical cord compression | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Cervical myelopathy | 3/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Cervical radiculopathy | 1/8030 (0%) | 5/7992 (0.1%) | 2/7933 (0%) | |||
Chorea | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Cognitive disorder | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Complex regional pain syndrome | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Dementia | 2/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Dementia Alzheimer's type | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Depressed level of consciousness | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Diabetic hyperosmolar coma | 2/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Diabetic neuropathy | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Dizziness | 6/8030 (0.1%) | 5/7992 (0.1%) | 6/7933 (0.1%) | |||
Dural arteriovenous fistula | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Dysarthria | 2/8030 (0%) | 0/7992 (0%) | 3/7933 (0%) | |||
Dyskinesia | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Embolic stroke | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Encephalomalacia | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Encephalopathy | 0/8030 (0%) | 1/7992 (0%) | 3/7933 (0%) | |||
Epidural lipomatosis | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Epilepsy | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Facial paralysis | 1/8030 (0%) | 2/7992 (0%) | 2/7933 (0%) | |||
Facial paresis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Generalised tonic-clonic seizure | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Guillain-Barre syndrome | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Haemorrhage intracranial | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Haemorrhagic stroke | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Headache | 4/8030 (0%) | 6/7992 (0.1%) | 0/7933 (0%) | |||
Hemiparesis | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Hydrocephalus | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Hypertensive encephalopathy | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Hypoaesthesia | 2/8030 (0%) | 4/7992 (0.1%) | 0/7933 (0%) | |||
Hypoxic-ischaemic encephalopathy | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
IIIrd nerve paralysis | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Intracranial aneurysm | 1/8030 (0%) | 4/7992 (0.1%) | 3/7933 (0%) | |||
Ischaemic cerebral infarction | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Ischaemic stroke | 2/8030 (0%) | 3/7992 (0%) | 8/7933 (0.1%) | |||
Lacunar infarction | 1/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Lacunar stroke | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Loss of consciousness | 6/8030 (0.1%) | 1/7992 (0%) | 1/7933 (0%) | |||
Lumbar radiculopathy | 1/8030 (0%) | 4/7992 (0.1%) | 3/7933 (0%) | |||
Mental impairment | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Metabolic encephalopathy | 2/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Migraine | 5/8030 (0.1%) | 2/7992 (0%) | 1/7933 (0%) | |||
Migraine with aura | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Monoparesis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Multiple sclerosis relapse | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Myelopathy | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Nerve compression | 0/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Nerve root compression | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Nervous system disorder | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Neurological symptom | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Neuromyopathy | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Neuropathy peripheral | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Normal pressure hydrocephalus | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Paraesthesia | 1/8030 (0%) | 2/7992 (0%) | 2/7933 (0%) | |||
Paraplegia | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Parkinsonism | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Presyncope | 2/8030 (0%) | 6/7992 (0.1%) | 4/7933 (0.1%) | |||
Quadriparesis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Quadriplegia | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Radial nerve palsy | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Radicular pain | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Radiculopathy | 1/8030 (0%) | 3/7992 (0%) | 0/7933 (0%) | |||
Sacral radiculopathy | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Sciatica | 1/8030 (0%) | 2/7992 (0%) | 2/7933 (0%) | |||
Seizure | 6/8030 (0.1%) | 8/7992 (0.1%) | 4/7933 (0.1%) | |||
Senile dementia | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Spinal claudication | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Spinal cord compression | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Spondylitic myelopathy | 1/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Status epilepticus | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Subarachnoid haemorrhage | 3/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Syncope | 19/8030 (0.2%) | 21/7992 (0.3%) | 31/7933 (0.4%) | |||
Thalamic infarction | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Toxic encephalopathy | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Transient global amnesia | 1/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Transient ischaemic attack | 22/8030 (0.3%) | 29/7992 (0.4%) | 28/7933 (0.4%) | |||
Tremor | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Trigeminal neuralgia | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Unresponsive to stimuli | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Vascular encephalopathy | 1/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Pregnancy, puerperium and perinatal conditions | ||||||
Abortion spontaneous | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Product Issues | ||||||
Device breakage | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Device connection issue | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Device dislocation | 1/8030 (0%) | 1/7992 (0%) | 4/7933 (0.1%) | |||
Device failure | 1/8030 (0%) | 1/7992 (0%) | 4/7933 (0.1%) | |||
Device loosening | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Device malfunction | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Device material issue | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Lead dislodgement | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Stent malfunction | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Psychiatric disorders | ||||||
Acute psychosis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Alcohol withdrawal syndrome | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Anxiety | 1/8030 (0%) | 0/7992 (0%) | 4/7933 (0.1%) | |||
Bipolar I disorder | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Bipolar disorder | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Confusional state | 3/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Delirium | 0/8030 (0%) | 1/7992 (0%) | 4/7933 (0.1%) | |||
Depression | 3/8030 (0%) | 5/7992 (0.1%) | 3/7933 (0%) | |||
Depression suicidal | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Disorientation | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Drug abuse | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Dysphoria | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Hallucination, auditory | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Hypomania | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Major depression | 2/8030 (0%) | 2/7992 (0%) | 3/7933 (0%) | |||
Mental status changes | 10/8030 (0.1%) | 5/7992 (0.1%) | 8/7933 (0.1%) | |||
Panic attack | 0/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Paranoia | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Post-traumatic stress disorder | 2/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Schizoaffective disorder | 0/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Schizophrenia | 1/8030 (0%) | 2/7992 (0%) | 2/7933 (0%) | |||
Substance abuse | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Suicidal ideation | 1/8030 (0%) | 4/7992 (0.1%) | 4/7933 (0.1%) | |||
Suicide attempt | 2/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Renal and urinary disorders | ||||||
Acute kidney injury | 36/8030 (0.4%) | 39/7992 (0.5%) | 31/7933 (0.4%) | |||
Acute prerenal failure | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Bladder outlet obstruction | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Bladder prolapse | 2/8030 (0%) | 3/7992 (0%) | 1/7933 (0%) | |||
Bladder spasm | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Calculus bladder | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Calculus urethral | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Calculus urinary | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Chronic kidney disease | 1/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Cystitis haemorrhagic | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Dysuria | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Haematuria | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Hydronephrosis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Hypertensive nephropathy | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Incontinence | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Nephrolithiasis | 7/8030 (0.1%) | 10/7992 (0.1%) | 11/7933 (0.1%) | |||
Nephropathy | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Nephrotic syndrome | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Renal artery stenosis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Renal colic | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Renal cyst haemorrhage | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Renal failure | 7/8030 (0.1%) | 21/7992 (0.3%) | 18/7933 (0.2%) | |||
Renal haematoma | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Renal impairment | 2/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Renal injury | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Renal mass | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Stag horn calculus | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Stress urinary incontinence | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Tubulointerstitial nephritis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Ureterolithiasis | 2/8030 (0%) | 3/7992 (0%) | 1/7933 (0%) | |||
Urethral stenosis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Urinary incontinence | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Urinary retention | 1/8030 (0%) | 3/7992 (0%) | 0/7933 (0%) | |||
Urine flow decreased | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Reproductive system and breast disorders | ||||||
Adnexa uteri mass | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Atrophic vulvovaginitis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Benign prostatic hyperplasia | 4/8030 (0%) | 5/7992 (0.1%) | 4/7933 (0.1%) | |||
Breast disorder | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Breast mass | 1/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Colpocele | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Cystocele | 4/8030 (0%) | 3/7992 (0%) | 1/7933 (0%) | |||
Dysfunctional uterine bleeding | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Endometrial hyperplasia | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Erectile dysfunction | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Female genital tract fistula | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Menorrhagia | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Metrorrhagia | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Ovarian cyst | 3/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Ovarian mass | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Pelvic adhesions | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Pelvic floor muscle weakness | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Pelvic prolapse | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Postmenopausal haemorrhage | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Prostatic obstruction | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Prostatitis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Prostatomegaly | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Rectocele | 2/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Spermatocele | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Uterine haemorrhage | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Uterine prolapse | 1/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Uterovaginal prolapse | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Vaginal haemorrhage | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Vaginal prolapse | 4/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Respiratory, thoracic and mediastinal disorders | ||||||
Acute respiratory distress syndrome | 2/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Acute respiratory failure | 7/8030 (0.1%) | 11/7992 (0.1%) | 4/7933 (0.1%) | |||
Asphyxia | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Aspiration | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Asthma | 9/8030 (0.1%) | 13/7992 (0.2%) | 10/7933 (0.1%) | |||
Asthma-chronic obstructive pulmonary disease overlap syndrome | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Asthmatic crisis | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Atelectasis | 0/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Bronchial hyperreactivity | 1/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Bronchiectasis | 0/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Bronchitis chronic | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Bronchospasm | 3/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Choking | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Chronic obstructive pulmonary disease | 29/8030 (0.4%) | 30/7992 (0.4%) | 31/7933 (0.4%) | |||
Cough | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Dyspnoea | 16/8030 (0.2%) | 24/7992 (0.3%) | 24/7933 (0.3%) | |||
Dyspnoea exertional | 1/8030 (0%) | 2/7992 (0%) | 3/7933 (0%) | |||
Dyspnoea paroxysmal nocturnal | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Emphysema | 0/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Eosinophilic pneumonia | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Epistaxis | 0/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Haemoptysis | 1/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Hydrothorax | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Hypercapnia | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Hypoventilation | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Hypoxia | 0/8030 (0%) | 6/7992 (0.1%) | 6/7933 (0.1%) | |||
Idiopathic pulmonary fibrosis | 1/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Interstitial lung disease | 1/8030 (0%) | 4/7992 (0.1%) | 4/7933 (0.1%) | |||
Laryngeal stenosis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Lung consolidation | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Lung infiltration | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Mediastinal mass | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Nasal congestion | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Nasal polyps | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Nasal septum deviation | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Obstructive airways disorder | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Pickwickian syndrome | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Pleural effusion | 6/8030 (0.1%) | 2/7992 (0%) | 6/7933 (0.1%) | |||
Pleurisy | 1/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Pneumonia aspiration | 2/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Pneumonitis | 1/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Pneumothorax | 2/8030 (0%) | 4/7992 (0.1%) | 4/7933 (0.1%) | |||
Pulmonary arterial hypertension | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Pulmonary embolism | 18/8030 (0.2%) | 10/7992 (0.1%) | 21/7933 (0.3%) | |||
Pulmonary fibrosis | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Pulmonary hypertension | 0/8030 (0%) | 2/7992 (0%) | 4/7933 (0.1%) | |||
Pulmonary mass | 3/8030 (0%) | 3/7992 (0%) | 2/7933 (0%) | |||
Pulmonary oedema | 1/8030 (0%) | 4/7992 (0.1%) | 3/7933 (0%) | |||
Pulmonary thrombosis | 2/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Respiratory arrest | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Respiratory disorder | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Respiratory distress | 3/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Respiratory failure | 8/8030 (0.1%) | 14/7992 (0.2%) | 10/7933 (0.1%) | |||
Sleep apnoea syndrome | 2/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Status asthmaticus | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Tachypnoea | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Tracheal stenosis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Vocal cord inflammation | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Skin and subcutaneous tissue disorders | ||||||
Angioedema | 3/8030 (0%) | 4/7992 (0.1%) | 1/7933 (0%) | |||
Dermal cyst | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Dermatitis bullous | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Diabetic foot | 3/8030 (0%) | 5/7992 (0.1%) | 1/7933 (0%) | |||
Diabetic ulcer | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Drug eruption | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Erythema multiforme | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Erythema nodosum | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Hyperhidrosis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Hypersensitivity vasculitis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Leukoplakia | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Melanocytic hyperplasia | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Panniculitis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Pruritus | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Rash | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Rash vesicular | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Skin ulcer | 2/8030 (0%) | 4/7992 (0.1%) | 1/7933 (0%) | |||
Stasis dermatitis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Swelling face | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Urticaria | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Social circumstances | ||||||
Activities of daily living impaired | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Immobile | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Physical assault | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Surgical and medical procedures | ||||||
Bladder operation | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Cardiac pacemaker replacement | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Colporrhaphy | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Coronary arterial stent insertion | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Coronary revascularisation | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Cystocele repair | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Gastric banding | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Hernia repair | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Hip arthroplasty | 2/8030 (0%) | 2/7992 (0%) | 3/7933 (0%) | |||
Hysterectomy | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Inguinal hernia repair | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Joint fluid drainage | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Knee arthroplasty | 1/8030 (0%) | 1/7992 (0%) | 3/7933 (0%) | |||
Ligament operation | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Medical device removal | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Oophorectomy | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Parovarian cystectomy | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Renal artery stent placement | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Renal stone removal | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Shoulder arthroplasty | 0/8030 (0%) | 2/7992 (0%) | 2/7933 (0%) | |||
Shoulder operation | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Spinal decompression | 0/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Spinal fusion surgery | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Spinal operation | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Tenoplasty | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Thyroidectomy | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Vascular operation | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Wound drainage | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Left hip surgical error | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Worsening osteoarthritis right hip replacement | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Vascular disorders | ||||||
Accelerated hypertension | 1/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Aneurysm | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Angiopathy | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Aortic aneurysm | 10/8030 (0.1%) | 4/7992 (0.1%) | 4/7933 (0.1%) | |||
Aortic aneurysm rupture | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Aortic arteriosclerosis | 1/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Aortic calcification | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Aortic dilatation | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Aortic dissection | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Aortic stenosis | 2/8030 (0%) | 3/7992 (0%) | 7/7933 (0.1%) | |||
Arterial occlusive disease | 1/8030 (0%) | 2/7992 (0%) | 2/7933 (0%) | |||
Arteriosclerosis | 1/8030 (0%) | 2/7992 (0%) | 3/7933 (0%) | |||
Arteriovenous fistula | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Bleeding varicose vein | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Blue toe syndrome | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Deep vein thrombosis | 12/8030 (0.1%) | 11/7992 (0.1%) | 12/7933 (0.2%) | |||
Extravasation blood | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Extremity necrosis | 3/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Haematoma | 2/8030 (0%) | 1/7992 (0%) | 4/7933 (0.1%) | |||
Hypertension | 18/8030 (0.2%) | 35/7992 (0.4%) | 21/7933 (0.3%) | |||
Hypertensive crisis | 4/8030 (0%) | 7/7992 (0.1%) | 14/7933 (0.2%) | |||
Hypertensive emergency | 1/8030 (0%) | 2/7992 (0%) | 2/7933 (0%) | |||
Hypotension | 7/8030 (0.1%) | 13/7992 (0.2%) | 9/7933 (0.1%) | |||
Hypovolaemic shock | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Intermittent claudication | 2/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Internal haemorrhage | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Ischaemia | 1/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Labile hypertension | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Leriche syndrome | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Lymphoedema | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Malignant hypertension | 1/8030 (0%) | 2/7992 (0%) | 3/7933 (0%) | |||
Neurogenic shock | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Orthostatic hypertension | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Orthostatic hypotension | 2/8030 (0%) | 3/7992 (0%) | 3/7933 (0%) | |||
Arterial thrombosis | 0/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Penetrating aortic ulcer | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Peripheral arterial occlusive disease | 2/8030 (0%) | 2/7992 (0%) | 4/7933 (0.1%) | |||
Peripheral artery aneurysm | 0/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Peripheral artery occlusion | 2/8030 (0%) | 3/7992 (0%) | 1/7933 (0%) | |||
Peripheral artery stenosis | 1/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Peripheral artery thrombosis | 2/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Peripheral ischaemia | 3/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Peripheral vascular disorder | 4/8030 (0%) | 3/7992 (0%) | 5/7933 (0.1%) | |||
Peripheral venous disease | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Phlebitis | 1/8030 (0%) | 0/7992 (0%) | 2/7933 (0%) | |||
Shock | 2/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Subclavian vein thrombosis | 0/8030 (0%) | 1/7992 (0%) | 0/7933 (0%) | |||
Systolic hypertension | 0/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Temporal arteritis | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Thrombophlebitis | 2/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Thrombophlebitis superficial | 1/8030 (0%) | 1/7992 (0%) | 2/7933 (0%) | |||
Thrombosis | 3/8030 (0%) | 2/7992 (0%) | 1/7933 (0%) | |||
Varicose vein | 1/8030 (0%) | 1/7992 (0%) | 1/7933 (0%) | |||
Vascular stenosis | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Venous thrombosis | 0/8030 (0%) | 2/7992 (0%) | 0/7933 (0%) | |||
Venous thrombosis limb | 0/8030 (0%) | 0/7992 (0%) | 1/7933 (0%) | |||
Femoral popliteal occlusive disease | 1/8030 (0%) | 0/7992 (0%) | 0/7933 (0%) | |||
Other (Not Including Serious) Adverse Events |
||||||
Celecoxib | Ibuprofen | Naproxen | ||||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 4268/8030 (53.2%) | 4363/7992 (54.6%) | 4337/7933 (54.7%) | |||
Blood and lymphatic system disorders | ||||||
Anaemia | 207/8030 (2.6%) | 405/7992 (5.1%) | 310/7933 (3.9%) | |||
Gastrointestinal disorders | ||||||
Constipation | 274/8030 (3.4%) | 344/7992 (4.3%) | 408/7933 (5.1%) | |||
Diarrhoea | 641/8030 (8%) | 538/7992 (6.7%) | 566/7933 (7.1%) | |||
Dyspepsia | 393/8030 (4.9%) | 424/7992 (5.3%) | 436/7933 (5.5%) | |||
Gastrooesophageal reflux disease | 401/8030 (5%) | 404/7992 (5.1%) | 387/7933 (4.9%) | |||
Nausea | 425/8030 (5.3%) | 482/7992 (6%) | 502/7933 (6.3%) | |||
Infections and infestations | ||||||
Bronchitis | 465/8030 (5.8%) | 471/7992 (5.9%) | 427/7933 (5.4%) | |||
Sinusitis | 373/8030 (4.6%) | 421/7992 (5.3%) | 375/7933 (4.7%) | |||
Upper respiratory tract infection | 584/8030 (7.3%) | 595/7992 (7.4%) | 560/7933 (7.1%) | |||
Urinary tract infection | 416/8030 (5.2%) | 452/7992 (5.7%) | 414/7933 (5.2%) | |||
Musculoskeletal and connective tissue disorders | ||||||
Arthralgia | 764/8030 (9.5%) | 659/7992 (8.2%) | 764/7933 (9.6%) | |||
Back pain | 542/8030 (6.7%) | 516/7992 (6.5%) | 547/7933 (6.9%) | |||
Osteoarthritis | 958/8030 (11.9%) | 859/7992 (10.7%) | 880/7933 (11.1%) | |||
Pain in extremity | 455/8030 (5.7%) | 422/7992 (5.3%) | 422/7933 (5.3%) | |||
Nervous system disorders | ||||||
Headache | 361/8030 (4.5%) | 409/7992 (5.1%) | 365/7933 (4.6%) | |||
Vascular disorders | ||||||
Hypertension | 762/8030 (9.5%) | 1008/7992 (12.6%) | 855/7933 (10.8%) |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Results Point of Contact
Name/Title | Pfizer Clinical Trials.gov Call Center |
---|---|
Organization | Pfizer, Inc |
Phone | 1-800-718-1021 |
ClinicalTrials.gov_Inquiries@pfizer.com |
- A3191172
- 2004-002441-13
- PRECISION TRIAL